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1 Introduction 
 
1.1 The mammalian cell cycle and its regulation 
The mammalian cell cycle consists of temporally distinct phases that include DNA 
replication (S-phase) and cell division or mitosis (M-phase) separated by two gap phases 
(G1 and G2-phase), which allow time for DNA repair and replication errors (Fig. 1). G1 
phase (occurring between M-phase and S-phase) is a critical stage during cell cycle, as 
during this phase the cell is responsive to various metabolic, stress and extracellular 
signals and the critical decision to enter S-phase (in other words, to cross the restriction 
point, R) is made, which commits the cell for the rest of the cell cycle (Pardee 1974). The 
next gap phase G2 is between S-phase and M-phase, which monitors the completion of 
DNA replication and genomic integrity before the cell starts dividing. The final phase of the  
 
!
Figure 1: The eukaryotic cell cycle and its regulation by cyclin-CDK complexes and CDK 
inhibitors (CKIs).  
Figure taken from (Dehay and Kennedy 2007). 
 
cell cycle, M-phase consists of mitosis (division of nucleus) and cytokinesis (division of 
cytoplasm). Mitosis is further divided into five distinct phases, prophase, prometaphase, 
metaphase, anaphase and telophase. During prophase the chromosomes condense and 
centrosomes move apart towards opposite spindle poles. Subsequently nuclear envelope 
breakdown occurs. During prometaphase, kinetochores (molecular structures at the 
centromeres of the chromosomes) capture the microtubules originating from both spindle 
poles. By the time the cell enters metaphase, all the chromosomes are aligned at the 
metaphase plate in equatorial plane. During anaphase the sister chromatids move 
towards the opposite poles of the cell. Telophase is comprised of reformation of nuclear 
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envelope around the daughter chromosomes at poles and chromosome decondensation. 
Finally, formation of a contractile ring at the midbody separates the parent cell into two 
daughter cells by the process of cytokinesis (Norbury and Nurse 1992). 
The orderly progression of mammalian cell cycle is regulated by a family of 
serine/threonine kinases known as cyclin dependent kinases (CDKs), which form active 
hetrodimeric complexes with cyclins (Morgan 1997). For example during early G1, CDK4 
and CDK6 form active complex with cyclin D, during late G1 CDK2 forms complex with 
cyclin E1 and E2, during S phase CDK2 is activated by cyclin A1 and A2, CDK1 controls 
entry into M-phase along with cyclin A and finally during M-phase CDK1 forms complex 
with cyclin B (Fig. 1) (Malumbres and Barbacid 2009). Besides being controlled by the 
fluctuating levels of cyclins during the cell cycle, CDK activity is also controlled by CDK 
inhibitors (CKIs). There are two families of CKIs, the INK4 family (composed of p16INK4a, 
p15INK4b, p18INK4c and p19INK4d) which inhibit CDK4 and CDK6 and hence only affect G1-S 
transition and CIP/KIP family (composed of p21Cip1, p27Kip1, p57Kip2) which affect the 
binding of cyclins D, E, A with their respective CDKs and hence affect both G1-S and G2-
M transitions (Sherr and Roberts 1999). 
In addition to being regulated by CDKs, the coordinated progression of cell cycle is also 
controlled by various other kinases, for example, checkpoint kinases (Chk), Polo like 
kinases (Plk) and Aurora family of kinases. Checkpoint kinases (Chk1 and Chk2) are 
activated in response to DNA damaging agents and provide cells time to repair the 
damage by inducing cell cycle arrest (Bartek and Lukas 2003). Plk1 is required for 
CDK1/Cyclin B activation, centrosome maturation, and spindle assembly as well as 
cytokinesis (Petronczki et al. 2008). Aurora kinases are implicated in mitosis and meiosis 
and play a key role in faithful segregation of the diploid content of genome into two 
daughter cells (see section 1.3).  
Genomic integrity is maintained by three major checkpoints during cell cycle, the G1-S 
checkpoint, G2-M checkpoint and spindle assembly checkpoint. G1-S checkpoint is 
activated due to DNA damage or DNA replication stress and is mediated via ATM/ATR-
Chk2(Chk1)-p53-p21 pathway, which arrests cells in G1 phase of the cell cycle. Any 
unrepaired damage in previous S/G1 phase or DNA damage in G2 phase activates the 
G2-M checkpoint, which inhibits the activity of cyclin B-CDK1 complex and hence 
prevents entry into mitosis until the damage is repaired (Kastan and Bartek 2004). Spindle 
assembly checkpoint (SAC) is activated in presence of unattached kinetochores during 
metaphase to anaphase transition which targets the anaphase promoting complex 
(APC/C) and prevents cell cycle progression until all the chromosomes are accurately 
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bioriented which in turn ensures accurate segregation of genome (Musacchio and Salmon 
2007). 
 
1.2 Transcriptional regulation during cell cycle  
Transcription during cell cycle generates the molecular components required for various 
essential processes (e.g. DNA replication, chromosome segregation etc.) and replenishes 
the proteins degraded during cell cycle progression and cell division. To regulate the 
expression of genes in a periodic manner, the process of transcription is intricately 
regulated and coupled to post-translational regulation during cell cycle and this whole 
mechanism is highly conserved across metazoans (Whitfield et al. 2002; Rustici et al. 
2004; Jensen et al. 2006). Of all the cyclically regulated proteins in cell, the most 
important ones are cyclins, which along with CDKs regulate the expression of a large 
number of genes at critical transitions along with E2F transcription factors (Koepp et al. 
1999; Murray 2004). Transcription mainly occurs during G1-to-S, G2-to-M and M-to-G1 
transition, of which transcription during M-to-G1 phase transition is the least explored (in 
humans) while during G1-to-S transition is the most studied. This is because of the 
important role of G1-S transition in regulating the ‘restriction point’ during the G1 phase of 
the cell cycle, which is deregulated in most of the cancers and is mainly regulated by 
E2F/pRb pathway (Weinberg 1995; Sherr 1996). E2F are a family of transcription factors 
whose target gene expression is regulated by pocket proteins (pRb, p130 and p107) 
(Dimova and Dyson 2005; Heuvel and Dyson 2008). Some of the E2F family members 
function as transcriptional activators (E2F1, E2F2 and E2F3A) whereas others function as 
transcriptional repressors (E2F3B, E2F4-8). However recent evidences suggest that they 
can switch their function from activation to repression and vice-versa (Chong et al. 2009; 
Lee et al. 2011; Weijts et al. 2012).  
 
!
Figure 2: G1-S control by E2F-pocket protein complexes.  
Figure adapted from (Bertoli et al. 2013). 
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pRb binds to activator E2Fs and repressor E2Fs (E2F4 and E2F5) are bound by p130 and 
p107 to repress transcription during early G1 (Takahashi et al. 2000). Phosphorylation of 
pocket proteins by G1 cyclin-CDKs dissociates them from their respective E2F partners 
and this in turn causes dissociation of repressive E2Fs from promoters allowing the 
activator E2Fs to bind to these promoters and hence activate target gene expression 
required for G1-S transition (Fig. 2) (Takahashi et al. 2000; Balciunaite et al. 2005). Once 
cells pass through this restriction-point, they initiate DNA replication and enter into S 
phase.  
RNA Polymerase II (RNAPII) performs transcription of all the coding genes in eukaryotes. 
RNAPII catalytic core (composed of 12 subunits), associates with general transcription 
factors (GTFs) such as TATA binding protein (TBP), TBP associated factors, TFIIB, TFIIE, 
TFIIF and TFIIH at the promoters of genes to regulate their expression (Hahn 2004). 
Transcription by RNAPII is regulated by phosphorylation of the C-terminal domain (CTD) 
of the largest subunit of RNAPII (Phatnani and Greenleaf 2006). This phosphorylation of 
CTD is in turn regulated during the cell cycle as various CTD kinases are members of the 
cyclin-dependent kinase (cdk) superfamily, including p34cdc2 (cdk1), cdk7, cdk8, and cdk9. 
Cdk7, a component of the general transcription factor TFIIH phosphorylates CTD at serine 
5 and serine 7 and is required for promoter clearance (Akhtar et al. 2009). Cdk8 functions 
as a part of mediator complex to phosphorylate CTD at serine 5 (Galbraith, Donner, and 
Espinosa 2010). Cdk9 functions as a part of PTEFb (positive transcription elongation 
factor) complex to phosphorylate CTD at serine 2 and converts it into elongating form 
(Price 2000). p34cdc2 phosphorylates CTD to inhibit transcription in vitro in yeast (Gebara 
et al. 1997).  
 
!
Figure 3: Differential phosphorylation of CTD of RNA Polymerase II during transcription 
cycle.  
Figure taken from (Sutherland and Bickmore 2009). 
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Hence, cyclin-CDK complexes are the connecting link between cell cycle and RNAPII 
transcription. Phosphorylation state of CTD dictates the transcriptional stage (pre-
initiation, initiation and elongation) of RNAPII (Fig. 3) (Egloff et al. 2012). 
Besides phosphorylating RNAPII at CTD, the cyclin-CDK complexes can phosphorylate 
transcription factors themselves. For example, cyclinA-Cdk2 phosphorylates E2Fs 
decreasing their DNA binding ability and hence transcription (Krek et al. 1994). Thus the 
transcription machinery and cell cycle are intricately related and regulated by cyclin-CDK 
complexes through phosphorylation of pRb, E2F and CTD of RNAPII (Dynlacht 1997; 
Bregman et al. 2000). 
 
1.3 Aurora kinases and there role in cancer 
The Aurora family of kinases was initially discovered in Drosophila melanogaster, where 
two family members are present. In yeast there is only one representative of this family 
known as Ipl1p, whereas mammals have three family members, Aurora A, Aurora B and 
Aurora C. In case of mammals, the three family members share around 70 % homology in 
their C-terminal catalytic domains (Fig. 4). The mammalian family members are closely 
related to AGC (cAMP-dependent, cGMP-dependent, protein kinase C) family of 
serine/threonine kinases and share a common consensus phosphorylation motif 
([R/K]x[S/T]Φ, in which x can be any amino acid and Φ is a hydrophobic residue) (Gold et 
al. 2006; Alexander et al. 2011). Their expression levels peaks during mitosis, during 
which each member has a distinct subcellular localization and function, ensuring that the 
full complement of genome is divided equally to future generations. 
!
Figure 4: Domain structure of Aurora family of kinases. 
Schematic representation of domain structure of human Aurora A, B and C. There size is 
represented (in amino acid numbers) on right and the numbers in percentage indicate sequence 
identities. The kinase domains are in green while the activating T-loops are shown in red. The 
destruction box (D-box, blue) and the D-box activating domain (DAD, or A-box, red) are 
responsible for degradation of Aurora A but not for Aurora B and C. A-box is absent in Aurora B 
and Aurora C. Figure taken from (Keen and Taylor 2004).  
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Despite the striking similarity in the catalytic domains of the three members of the Aurora 
family in mammals, they have different localizations and functions during cell cycle 
progression (for details see Fig. 5). Aurora A localizes to centrosomes and mitotic spindle 
and has a function in centrosome maturation and separation as well as in spindle 
assembly (Hirota et al. 2003; Barr and Gergely 2007). It’s inhibition leads to mitotic arrest. 
On the other hand Aurora B localizes on chromosomes and midbody and is required for 
spindle assembly checkpoint and cytokinesis (Carmena and Earnshaw 2003; Vader 
2006). Inhibition of Aurora B leads to a catastrophic mitosis, leading to G1 arrest and cell 
death by apoptosis.  
 
!
 
Figure 5: Subcellular localizations of Aurora kinases A and B during mitosis. 
The schematic shows the relative localizations of Aurora A and Aurora B during mitosis. During 
prophase Aurora A (in green) is concentrated at centrosomes, and Aurora B (in red) localizes 
along the chromosome arms.  By metaphase, Aurora A is on microtubules near the spindle poles 
while Aurora B is at kinetochores near to centromeres. As the cells enter Anaphase, Aurora A is 
on the polar microtubules and Aurora B becomes highly concentrated at the spindle midzone at 
the cell cortex near the site of the cleavage furrow. Finally during cytokinesis both the kinases 
are concentrated at the midbody and there levels drop as the cell exits mitosis. Figure taken from 
(Carmena and Earnshaw 2003). 
 
Information about Aurora C remains scarce. It is mainly expressed in male germline and 
can take over the function of Agurora B in its absence by associating with the 
chromosomal passenger complex (CPC) (Sasai et al. 2004; Avo Santos et al. 2011; 
Fernandez-Miranda et al. 2011). Recently it was shown that overexpression of Aurora C 
causes degradation of Aurora B (Lin et al. 2014). 
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1.3.1 Role of Aurora B in cell cycle 
Aurora B has various functions during the cell cycle as a part of the chromosomal 
passenger complex (CPC) (Ruchaud et al. 2007; Carmena et al. 2012). CPC consists of 
the enzymatic component Aurora B, a scaffold protein inner centromere protein (INCEP) 
and two non-enzymatic subunits Survivin and Borealin. The protein stability of each 
subunit of CPC depends on protein-protein interactions within the complex, hence 
knockdown of any of the components or chemical inhibition results in a similar phenotype 
in wide range of organisms (Adams et al. 2001; Biggins and Murray 2001; Lens et al. 
2003; Gassmann 2004; Vader et al. 2006; Klein et al. 2006; Xu et al. 2009; Kelly et al. 
2010). Aurora B has three important functions during the cell cycle: 
1) Chromosome condensation - At the beginning of mitosis, in prophase Aurora B 
mediates sister chromatid separation by causing cohesin dissociation from 
chromosome arms (Giménez-Abián et al. 2004; Dai et al. 2006; Nishiyama et al. 
2013), loading of Condensin I complex on the chromosome arms (Lipp et al. 
2007), or by phosphorylating H3. Histone H3 is a substrate of Aurora B, which gets 
phosphorylated at Ser10 during mitosis and is a widely used mitotic marker 
(Crosio et al. 2002; Hirota et al. 2005). H3S10 is necessary for chromosome 
condensation in Drosophila (Giet and Glover 2001), but in humans this 
modification is implicated in chromosome condensation as well as dissociation of 
HP1 from chromatin during mitosis (Hirota et al. 2005; Crosio et al. 2002). In 
mammalian cells an additional phosphorylation at Ser28 is required for 
chromosome condensation (Goto et al. 2002).  
2) Spindle assembly checkpoint - The spindle assembly checkpoint (SAC) prevents 
the metaphase to anaphase transition until all the chromosomes are accurately bi-
oriented (Musacchio and Salmon 2007). During pro-metaphase and metaphase 
Aurora B becomes highly concentrated at inner centromeres and performs ‘error 
correction’ by regulating microtubule-kinetochore attachments through 
phosphorylation of a number of substrates like, MCAK (Lan et al. 2004), 
KNL1/Mis12/Ndc80 complex (Welburn et al. 2010; Chan et al. 2012) and Mps1 
(Biggins 2001; Santaguida et al. 2011; Saurin et al. 2011). Aurora B resolves 
syntelic attachments and converts them to amphitelic attachments (for details see 
Fig. 6). Aurora B generates unattached kinetochores which are sensed by SAC 
and hence keeps this mitotic checkpoint active until all the incorrect attachments 
are resolved (Ditchfield et al. 2003; Hauf et al. 2003; Nezi and Musacchio 2009; 
Maldonado and Kapoor 2011). 
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3) Cytokinesis – The final stage of cell cycle is cytokinesis, which generates two 
daughter cells by formation of actomyosin ring at the cell equator. Cytokinesis 
requires proper functioning of the centralspindlin complex [composed of GTPase 
activating protein (GAP) MgcRacGAP and a kinesin, MKLP1] (Zhao and Fang 
2005; Neef et al. 2006) whose activity in turn is regulated by Aurora B (Minoshima 
et al. 2003; Touré et al. 2008; Guse et al. 2005; Douglas et al. 2010). Besides this, 
Aurora B also phosphorylates other cytoskeletal proteins, like vimentin (Goto et al. 
2003), myosin II regulatory light chain (Murata-Hori et al. 2000), desmin and GFAP 
(Kawajiri et al. 2003) required for abscission of the cell at correct time (Norden et 
al. 2006; Ozlu et al. 2010). 
 
 
Figure 6: Chromosome bi-orientation at metaphase plate. 
Schematic representation of different types of kinetochore-microtubule attachments during 
metaphase. Correctly bi-oriented chromosomes show amphitelic attachment (with the sister 
kinetochores attached to opposite poles, lower center). Mal-oriented chromosomes show 
monotelic/mono-oriented attachment (only one kinetochore is attached to one pole, lower left), 
merotelic attachment (one kinetochore is attached to both poles, upper center) or syntelic 
attachments (both kinetochores are attached to the same pole, lower right). Figure taken from 
(Keen and Taylor 2004). 
 
Although Aurora B mainly functions in mitosis, a recent study reported it’s function in 
interphase where Aurora B phosphorylates and mediates degradation of p53 (Gully et al. 
2012). Mice in which one allele of Aurora B is disrupted develop tumors, signifying the 
importance of Aurora B in maintaining genome integrity (Fernandez-Miranda et al. 2011). 
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1.3.2 Regulation of Aurora B kinase function 
Aurora B is highly regulated during the cell cycle to execute an orderly and timely 
phosphorylation of its substrates. The mechanisms that regulate Aurora B are discussed 
below: 
• Phosphorylation- In order to have kinase activity, Aurora B must be 
phosphorylated at a key threonine residue (T232) in its T-loop. This is 
accomplished by auto-phosphorylation induced by a conformational change upon 
interaction of Aurora B with the C-terminal IN-box of INCEP (Yasui et al. 2004; 
Sessa et al. 2005). Further the phosphorylation of substrates by Aurora B is 
counteracted by antagonistic phosphatases protein phosphatase 1 (PP1) and 
protein phosphatase 2A during mitosis (Liu et al. 2010; Foley et al. 2011). 
• Localization- Substrate specificity of Aurora B during mitosis is determined by its 
differential localization which is dictated by its interaction with various protein 
partners. For example, two non-enzymatic proteins Survivin and Borealin along 
with INCEP, target Aurora B to different sites such as chromosome arms and inner 
centromere by docking to these sites and hence function as ‘passenger proteins’ 
during cell division (Vader et al. 2006). 
• Ubiquitin mediated proteolysis- Aurora B is targeted for degradation by the E3 
ubiquitin ligase, anaphase-promoting complex/cyclosome (APC/C). APC/C 
mediates proteasomal degradation of Aurora B by ubiquitylation in conjunction with 
cdc20 homolog 1 (Cdh1) as the cells exit mitosis to ensure G1 cells have very low 
Aurora B protein levels (Stewart and Fang 2005). 
 
1.3.3 Role of Aurora B kinase in cancer and inhibitors against Aurora B 
Cancer is a disease whose characteristic features include chromosomal rearrangements 
and aneuploidy. As Aurora B has key functions in spindle assembly, mitotic checkpoint 
and chromosome segregation, it is reported to be deregulated in a wide range of cancers 
for example, NSCLC (non small cell lung cancer), colon and pancreatic cancer to name a 
few (Bischoff et al. 1998; Adams et al. 2001). Both the activity as well expression levels of 
Aurora B are increased in cancer and this is associated with poor prognosis as well. Also 
ectopic expression of Aurora B has been reported to cause transformation of cells in 
culture (Ota et al. 2002). This extensive correlation of Aurora B with cancer provides the 
basis for its importance as a target for chemotherapy (Keen and Taylor 2004; Girdler 
2006; Gully et al. 2010). A variety of chemical inhibitors against Aurora B have been 
developed so far, some of the examples being ZM447439 (Ditchfield et al. 2003), 
Hesperadin (Hauf et al. 2003), VX680 (Harrington et al. 2004) and AZD1152 (Mortlock et 
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al. 2007). These chemical compounds are competitive inhibitors of the ATP binding site of 
Aurora B. 
ZM447439 is a quinazoline derivative and was initially thought to inhibit both Aurora A and 
B. But further in vitro studies revealed that it had 20 times more specificity towards Aurora 
B and the cellular phenotypes were consistent with Aurora B inhibition (Ditchfield et al. 
2003). 
AZD1152, a member of 5-acetanilide-substituted 3-aminopyrazoles series is a highly 
selective Aurora B kinase chemical inhibitor (IC50 of 0.37 nM for Aurora B in contrast to 
1368 nM for Aurora A). It is a dihydrogen prodrug which is highly soluble in pH adjusted 
aqueous solutions and undergoes rapid conversion to active form AZD1152-HQPA in vivo 
(Mortlock et al. 2007; Wilkinson et al. 2007). 
 
1.4 The cellular stress response and its relevance for cancer therapy 
Cellular stress response is a defense mechanism elicited when cells are challenged with 
adverse conditions such as damage to DNA/protein, hypoxia, metabolic constraints, 
oxidative stress or oncogene activation. The severity and duration of stress determine the 
output, which could be either cell survival or cell death (by apoptosis, necrosis or 
autophagy) (Kültz 2005; Fulda et al. 2010). In addition to integrating the extracellular and 
intracellular stimuli, the cellular stress response also determines the efficacy and outcome 
of a chemotherapeutic regimen. The p53 tumor suppressor pathway and mitogen 
activated protein kinase pathway (MAPK) standout in this respect. 
 
1.4.1 The p53 tumor suppressor pathway 
Central to regulation of most of the stress signaling in a cell and mutated/deregulated in 
more than 50 % human tumors is p53, a tumor suppressor protein also known as “the 
guardian of genome” (Lane 1992; Vogelstein et al. 2000). p53 is a transcription factor 
which prevents tumor development by causing G1 cell cycle arrest, apoptosis and 
senescence under adverse stressful conditions by activation of a number of target genes 
including p21, GADD45, BAX and 53BP1 (Fig. 7) (Vousden and Prives 2009; Bieging et 
al. 2014). Some of the p53 functions are also independent of its transcriptional activity as 
summarized in Fig. 7 (Moll et al. 2005; Sengupta and Harris 2005; Suzuki et al. 2009). 
Elegant recent findings demonstrate that other functions of p53 in DNA repair, regulation 
of metabolism and oxidative stress also contribute to its tumor suppressive functions 
(Brady et al. 2011; Li et al. 2012; Valente et al. 2013) besides its classical functions in 
preventing tumor growth by cell cycle arrest, apoptosis and senescence known so far.  
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Figure 7: p53 signaling.  
Figure taken from (Brown et al. 2009). 
 
The half-life of p53 protein is very short under unstressed conditions as it is continuously 
degraded by the E3 ubiquitin ligase MDM2 through proteasome-mediated degradation 
(Momand et al. 1992; Kubbutat et al. 1997). In response to a wide range of stress (DNA 
damage, hypoxia, damage to mitotic spindle, heat shock, oncogenes or unfolded 
proteins), various signaling proteins phosphorylate p53, preventing its interaction with 
MDM2 and hence its degradation. This is followed by other modifications (acetylation and 
methylation) of p53 and it’s binding as a homotetramer to its binding site (p53BS1 and 2) 
on the target gene promoters resulting in their induction (Vousden and Lane 2007; Riley 
et al. 2008; Kruse and Gu 2009).  
The p53 signaling is deregulated in tumors by three common mechanisms, (a) mutations 
in DNA binding domain of p53 and hence preventing its binding to DNA, (b) mutations that 
prevent the proper folding and oligomerization of p53 and (c) overexpression of p53 
regulatory proteins such as MDM2. Hence, not surprisingly all these mechanisms are 
being currently explored in clinic for effective cancer therapy (Muller and Vousden 2013; 
Hoe et al. 2014). 
 
1.4.2 Mitogen activated protein kinase pathway (MAPK pathway) 
The mitogen-activated protein kinases (MAPKs) are a family of stress kinases that serve 
to integrate the signals from a number of environmental and cellular stimuli to activate 
cellular responses. Of all the kinases in the eukaryotic genome (around 518 in humans) 
MAPKs are involved in most of the signaling, which is highly conserved from yeast to 
mammals (Qi and Elion 2005). Each MAPK cascade is composed of three tiers of kinases 
MAPKKK (MAP3K, MAPK-kinase-kinase), MAPKK (MAP2K, MAPK-kinase) and MAPK 
and kinases in each tier phosphorylate and activate the members of next tier (Fig. 8). In 
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humans, the MAPKs are composed of four subfamilies; (1) ERKs (extracellular signal-
regulated kinases), (2) JNK/SAPK (c-Jun N-terminal related kinases or stress activated 
protein kinases), (3) p38-MAPK, (4) ERK5/big MAPK-1 (BMK1), classified by the MAPK at 
the end of the phosphorylation cascade (Raman et al. 2007). Signaling by ERK is 
activated by growth factors and results in cell growth and differentiation (Shaul and Seger 
2007). JNK and p38-MAPK signaling is mainly activated by inflammatory cytokines, 
environmental stress as well as genotoxic stress and they contribute to cell cycle 
regulation, cell differentiation, apoptosis and inflammation (Wagner and Nebreda 2009). 
Growth factors as well as cellular stress activate the ERK5 cascade leading to 
angiogenesis, anti-apoptosis, cell proliferation and differentiation (Wang and Tournier 
2006). 
 
!
Figure 8: General cascade of MAPK pathways.  
Figure taken from (Kumar et al. 2003). 
 
The p38 MAPK family is composed of four family members: MAPK11 (p38α), MAPK12 
(p38β), MAPK13 (p38γ) and MAPK14 (p38δ), which differ in their expression profiles, 
substrate specificity and sensitivity towards chemical inhibitors such as SB202190 and 
BIRB796. p38α is ubiquitously expressed in most cell types, whereas the expression of 
other isoforms is more restricted to certain tissues (e.g.  p38β in brain, p38γ skeletal 
muscle, p38δ in endocrine glands). p38α, the mammalian MAPK orthologue of Hog1 (the 
osmosensing MAPK of Saccharomyces cerevisiae) is the most extensively characterized 
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isoform among all (Cuadrado and Nebreda 2010).  
p38 MAPK, a serine/threonine kinase can function both as a tumor suppressor as well 
oncogene depending on the intensity and duration of stress, the cell type and cross talk 
with other signaling pathways. For example it halts cell cycle progression in response to 
DNA damage and other environmental insults (Bulavin et al. 2001), but can also induce 
angiogenesis under hypoxic conditions (Pages 2000). p38 MAPK has various 
physiological functions such as myogenic differentiation, keratinocyte differentiation and 
cell migration (Wu et al. 2000; Efimova 2003; Rousseau et al. 1997). p38 MAPK regulates 
cell cycle checkpoints at G0, G1/S and G2/M transitions during the cell cycle. By 
regulating the cyclin levels (cyclin A or D1), phosphorylation of retinoblastoma protein 
(pRb) and phosphorylation of p53 (Ser33 and Ser46), p38 has and effect on G1/S 
transition (Ambrosino and Nebreda 2001; Bulavin et al. 1999; Sanchez-Prieto et al. 2000). 
G2/M checkpoint activated by various stress stimuli is controlled by p38 MAPK through 
activation of MAPKAP-K2, which phosphorylates Cdc25B and Cdc25C causing their 
translocation into cytoplasm (Mikhailov et al. 2005; Manke et al. 2005). Besides this, p38 
MAPK also plays an important role in gene expression control (Nadal et al. 2011). 
Regulation of p38 MAPK is mainly by dual phosphorylation, auto-phosphorylation, 
phosphatases, and scaffold proteins (Kyriakis and Avruch 2001; Ge 2002; Keyse 2000; 
Owens and Keyse 2007). Due to the critical relevance of p38 MAPK pathway in 
proliferation control and apoptosis, it is deregulated in array of cancer types and is a 
attractive clinical target (Wagner and Nebreda 2009). 
1.5 Aneuploidy and cancer 
Chromosomal instability (CIN), a term assigned jointly for aneuploidy (numerical/whole- 
chromosome alterations) and structural chromosome alterations 
(translocations/deletions/insertions) is a hallmark of cancer (Mertens et al. 1994; Mertens 
et al. 1997; Lengauer et al. 1998; Weaver and Cleveland 2007). There are different 
mechanisms, which can generate aneuploidy as summarized in Fig. 9; (a) Mitotic 
checkpoint defects - Compromised SAC (due to loss or gain of individual components 
such as BUBR1), can cause abrupt entry into anaphase despite the presence of 
unattached kinetochores resulting in daughter cells with a gain or loss of chromosome(s). 
In fact a number of cancers have been reported to have mutated or altered expression 
and gene silencing (by methylation) of SAC components (Wang et al. 2004; Kops et al. 
2005; Park et al. 2007; Haruta et al. 2008). (b) Cohesion defects - Inability to separate 
sister chromatids during mitosis due to defects in components of the molecular machinery 
that keeps the sister chromatids attached (e.g. separase, cohesin, securin), also 
contributes to aneuploidy. Aneuploid cancers show a high correlation with somatic 
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mutations in the protein components required for attachment of sister chromatids (Barber 
et al. 2008; Zhang et al. 2008). (c) Merotelic attachments - Defects to resolve merotelic 
attachments during mitosis often result in misseggregations and lagging chromosomes 
resulting in aneuploidy (Cimini 2008). Merotelic attachments arise due to an increase in 
number of centrosomes or and increased stability of kinetochore-microtubule attachments 
(Ganem et al. 2009; Bakhoum et al. 2009). Cancer cells also show high frequency of 
merotelic attachments (Cimini et al. 2001; Cimini 2008). 
 
!
Figure 9: Different mechanisms that generate aneuploidy during mitosis.  
For details see text. Figure taken from (Holland and Cleveland 2009). 
 
(d) Multiploar mitotic spindles – Multipolar spindles arising due to multiple centrosomes 
allow the cells to undergo division, but often result in merotelic attachments and hence 
aneuploidy (Brinkley 2001; Nigg 2002; Silkworth et al. 2009). Centrosome amplification 
occurs in primary human tumors and is highly correlated with CIN (Pihan et al. 2003; Nigg 
2006). 
Extensive studies in yeast and mammalian studies implicate that aneuploidy reduces the 
fitness and generates a stressed state (Torres et al. 2007; Williams et al. 2008). The 
numerical change in chromosome number reflects into transcriptome and proteome of the 
aneuploid cells. Aneuploid yeast cells display a specific gene signature known as 
‘’Environmental Stress Response’’ (ESR) (Torres et al. 2007; Pavelka et al. 2010). 
Disturbed protein balance due to aneuploidy activates the ubiquitin-proteasome pathway 
and chaperone pathways, which relives the protein burden on the cell by causing their 
degradation. This also generates a metabolic and energetic stress on the cell (Torres et 
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al. 2010; Stingele et al. 2012; Oromendia and Amon 2014). As aneuploidy is associated 
with a specific stress response and cancer cells have developed adaptations to tolerate it, 
aneuploidy might be an interesting target for clinic.  
Aneuploidy is one of the ‘hallmarks’ of cancer as it is associated with around 90 % solid 
tumors and more than 50 % hematopoietic cancers in humans (Mitelman Database of 
Chromosome Aberrations and Gene Fusions in Cancer, 2014). But aneuploidy is not an 
accurate predictor of tumor susceptibility in mice models of mitotic checkpoint dysfunction 
and it is also associated with reduced proliferation rates of yeast and mammalian cells 
under in vitro conditions. For instance, mice which are prone to aneuploidy (due to 
mutations of various components of SAC), develop spontaneous tumors very late (>18 
months) and only a fraction of aneuploid mice develop spontaneous tumors (Holland and 
Cleveland 2009), trisomic MEFs have proliferation defects and do not immortalize or 
undergo immortalization quite late (Williams et al. 2008) and haploid yeast strains with an 
extra chromosome do not proliferate (Torres et al. 2007). This discrepancy between 
observed strong association of aneuploidy with cancer (which grow rapidly) and adverse 
effects of aneuploidy on growth rate and a poor correlation with tumor susceptibility in 
mice is termed as ‘aneuploidy paradox’ (Sheltzer and Amon 2011). The most suitable 
explanation for this is the differences in the extracellular environments and genetic context 
of the tumor cells in comparison to the cells grown in culture. Under culture conditions, 
mammalian and yeast cells are selected for growing fast, whereas tumor cells are 
continuously adapting to the varying intracellular and extracellular conditions resulting in 
slower growth rate, which might provide additional advantages, such as acquisition of 
additional mutations that help them to ameliorate the imbalances in proteome due the 
aneuploid karyotype resulting in a more aggressive phenotype (Araujo et al. 2007; 
Anjomshoaa et al. 2009; Torres et al. 2008; Torres et al. 2010). In summary, aneuploidy 
can suppress or promote tumorigenesis depending on the cell type and genetic 
background (Weaver and Cleveland 2007; Holland and Cleveland 2009; Gordon et al. 
2012; Holland and Cleveland 2012). 
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1.6 Objectives of thesis  
The fact that Aurora B kinase is overexpressed in a variety of cancers and has enzymatic 
kinase activity (enabling it to be inhibited by chemical compounds) makes it an attractive 
target for cancer therapy. Currently two Aurora B inhibitors AZD1152 and BI811283 are in 
phase III and phase II clinical trials respectively (Marzo and Naval 2013). More detailed 
understanding of the cellular signaling pathways regulated by Aurora B is required to 
explain the side effects as well as to provide biomarkers of response, for better evaluation 
of these chemical inhibitors in clinic. Aims of this thesis were: 
1) To study the mitotic stress signaling pathways activated due to Aurora B inhibition 
using two small molecule inhibitors of Aurora B (ZM447439 and AZD1152-HQPA) 
as chemical tools. 
2) To further study the therapeutic implications of Aurora B inhibitors in combination 
therapy for treatment of cancer. 
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2 Materials and Methods 
 
2.1 Materials 
 
2.1.1 Chemical stocks and reagents 
 
Unless specified, commonly used chemicals were purchased from AppliChem, Roth, 
Invitrogen, Invivogen or Sigma with analysis quality. 
 
 
Chemical Stock concentration 
Agarose Ready to use 
AICAR (AMPK activator) (Biomol) 20 mM in DMSO 
Ammonium persulfate (APS) 10 % in H2O 
AZD1152-HQPA (Aurora B kinase 
inhibitor) (Selleckchem) 10 mM in DMSO 
BIRB796 (p38 MAP kinase inhibitor) 
(Selleckchem) 10 mM in DMSO 
Bovine serum albumin (BSA) 20 mg/ml in H2O 
BrdU 10 mg/ml in 1X PBS 
Cycloheximide 10 mg/ml in H2O 
Doxorubicin 1.7 mM 
DMSO Ready to use 
dNTPs 2 mM dATP, dCTP, dGTP, dTTP each 
DTT 1 M in H2O 
Ethidium bromide 10 mg/ml in H2O 
H2DCF-DA (Molecular Probes) 20 mM in anhydrous DMSO 
Hoechst 33258 10 mg/ml in H2O 
Hoechst 33342 Ready to use 
ImmuMount (Shandon) Ready to use 
KU5593 (ATM kinase inhibitor) (Selleck) 10 mM in DMSO 
Low melting agarose Ready to use 
Luminol 250 mM in DMSO 
MitoSox Red (Life Technologies) 5 mM in DMSO 
p-Coumaric acid 90 mM in DMSO 
PMSF (Phenylmethylsulphonyl- 
fluoride) (Roche) 10 mg/ml in isopropanol 
Polybrene (Hexadimethrine bromide) 4 mg/ml in H2O 
Ponceau S solution 0.1 % Ponceau S in 5 % acetic acid 
Propidium iodide (PI) 1 mg/ml in H2O 
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2.1.2 Antibiotics 
 
Antibiotic Stock concentration Final Concentration Use for cell line 
Ampicillin 100 mg/ml 100 µg/ml in LB-medium DH5α (E-coli) 
Blasticidin 10 mg/ml 10 µg/ml in DMEM U2OS-EcoR-Neo 
Puromycin 10 mg/ml 2 µg/ml in DMEM U2OS-EcoR-Neo 
 
2.1.3 Enzymes 
 
Enzymes  Company 
Absolute QPCR SYBER Green Mix ThermoFisher 
DNase I, RNase free Roche 
Fast Alkaline Phosphatase (1 U/µl) Fermentas 
M-MLV-RT Transcriptase (200 U/µl) ThermoFisher 
Pfu DNA Polymerase (2.5 U/µl) Promega 
Phusion High Fidelity DNA Polymerase  
(2 U/µl) Finnzymes 
Restriction Endonucleases New England Biolabs (NEB), Fermentas 
RiboLock RNase-Inhibitor (40 U/µl) Fermentas 
T4-DNA Ligase (400 U/µl) New England Biolabs (NEB) 
 
Protease Inhibitor Cocktail Sigma ready to use 
Proteinase K 10 mg/ml in 50 mM Tris pH 8.0/ 1 mM CaCl2 
Protogel 30 % (Biozym) Ready to use 
Random Primer (Roche) 500 mg/ml in H2O 
RNase A 10 mg/ml in 10 mM Tris-HCl pH 7.4, 150 mM NaCl 
Sodium dodecyl sulfate (SDS) 20 % (w/v) in H2O 
SB202190 (p38 MAP kinase inhibitor) 10 mM in DMSO 
Tetramethylethylenediamine (Temed) 99 %  Ready to use 
Trizol/Trifast (total RNA isolation reagent) 
(Peqlab/Thermo) Ready to use 
Thymidine 200 mM in H2O 
VE821 (ATR kinase inhibitor) (Tinib-Tools) 10 mM in DMSO 
ZM447439 (Aurora kinase Inhibitor) (Enzo) 10 mM in DMSO 
4,5-Dihydroxy-1,3-benzenedisulfonic acid 
disodium salt (Tiron) (superoxide anion 
scavenger) 
100 mM in H2O 
17AAG (HSP90 inhibitor) (Selleckchem) 20 mM in DMSO 
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2.1.4 Molecular kits and Protein/DNA markers !
Kits Company 
Jetstar Gel Extraction kit Genomed 
GeneRulerTM DNA Ladder Fermentas 
Plasmid Midi-/Maxi-preps kit Invitrogen 
PageRulerTM Prestained Protein Ladder Fermentas 
QIAquick PCR purification kit Qiagen 
 
 
2.1.5 Devices 
 
Device  Company 
Agarose gel electrophoresis system  Peqlab                                
Bioruptor  Diagenode 
Centrifuges Eppendorf (5417R and 5415D) 
 Heraeus (Megafuge 1.0R) 
FACS Beckman Coulter (Cytomics FC500) 
Incubators Heraeus 
 Nunc 
Microscopes  Confocal (Nikon Eclipse Ti) 
 Fluorescence (Leica DMI 6000B) 
Mx3000 qPCR Agilent technologies 
Nanodrop Theromo Scientific (Nanodrop 2000) 
SDS-PAGE Gel Electrophoresis system  BIO-RAD 
 
 
2.1.6 Buffers 
 
2.1.6.1 General buffers !
5X DNA Loading buffer 
                       15 % Ficoll 
0.05 % Bromophenol blue 
0.05 % Xylene cyanol 
0.05 M EDTA 
 
0.5 M EDTA pH 8.0 
0.5 M EDTA 
adjust pH to 8.0 with NaOH pellets 
 
2X HBS 
280 mM NaCl 
1.5 mM Na2HPO4  
50 mM HEPES-KOH, pH 7.05 
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Miniprep Solution S1 
50 mM Tris-HCl, pH 8.0 
10 mM EDTA 
100 µg/ml RNase A 
 
Miniprep Solution S2 
200 mM NaOH 
1 % SDS 
 
Miniprep Solution S3 
3.1 mM Potassium Acetate 
adjust pH to 8.0 with glacial acetic acid 
 
10X PBS 
130 mM NaCl 
3 mM KCl 
64 mM Na2HPO4 
15 mM KH2PO4 
adjust pH to 7.4 with HCl 
  
50X TAE buffer 
200 mM Tris base 
250 mM glacial acetic acid 
500 mM EDTA, pH 8.0 
 
10X TE 
100 mM Tris-HCl, pH 7.5 
10 mM EDTA 
 
20X SSC 
3 M NaCl 
0.3 M Na-Citrate 
adjust pH to 7.0 with NaOH 
 
 
2.1.6.2 Buffers for whole cell lysates 
 
TNN buffer 
50 mM Tris-HCl, pH 7.5 
120 mM NaCl 
5 mM EDTA 
0.5 % NP-40 
10 mM Na4H2PO7 
2 mM Na3VO4 
100 mM NaF 
PIC (Sigma) 1:500 (added freshly) 
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Bradford Solution 
50 mg Coomassie Brilliant Blue G 
23.75 ml ethanol 
50 ml 85 % (v/v) ortho-phosphoric acid 
add to 500 ml H2O 
filter twice 
 
 
2.1.6.3 Buffers for immunoblotting 
 
4X Upper stock for SDS gels 
33 g Tris 
10 ml SDS (20 %) 
add to 500 ml H2O, adjust to pH 6.8 
 
4X Lower stock for SDS gels 
90.85 g Tris 
10 ml SDS (20 %) 
add to 500 ml H2O, adjust to pH 8.8 
 
Acrylamide buffer for SDS-gels (Protogel) 
30 % (w/v) acrylamide 
0.8 % (w/v) N,N’-methylenbisacrylamide 
 
Blotting buffer (1X) 
0.6 g Tris 
2.258 g Glycin 
150 ml methanol 
add to 1 l H2O 
 
Blocking solution 
3 % (w/v) milk powder in 0.05 % TBST, or 
5 % (w/v) milk powder in 0.1 % TBST (for cell signaling antibodies) 
 
Electrophoresis sample buffer (ESB) (3X) 
300 mM Tris-HCl, pH 6.8 
15 mM EDTA 
150 mM DTT 
12 % (w/v) SDS 
15 % (w/v) glycerol 
0.03 % (w/v) bromophenol blue 
 
0.15 M NaCl 
 
Ponceau S 
0.1 % Ponceau S 
5 % glacial acetic acid 
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SDS running buffer (10X) 
144 g Glycin 
30 g Tris 
10 g SDS 
add to 1 l H2O 
 
Substrate solution 
10 ml 100 mM Tris-HCl, pH 8.5 
50 µl 250 mM luminol 
22 µl 90 mM p-coumaric acid 
3 µl 30 % H2O2 
 
TBST 
0.05 % Tween 20 in 1X TBS, or 
0.1 % Tween 20 in 1X TBS 
 
 
2.1.6.4 Buffers for Chromatin Immunoprecipitation (ChIP) 
 
Cell lysis buffer 
5 mM PIPES, pH 8.0 
85 mM KCl 
0.5 % NP-40 
PIC 1:500 (added freshly) 
PMSF 1mM (added freshly) 
 
Nuclei lysis buffer 
50 mM Tris-HCl, pH 8.1 
10 mM EDTA 
1 % SDS 
PIC 1:500 (added freshly) 
PMSF 1mM (added freshly) 
 
IP Dilution buffer 
0.01 % SDS 
1.1 % Triton 
1.2 mM EDTA 
16.7 mM Tris-HCl, pH 8.2 
167 mM NaCl 
PIC 1:500 (added freshly) 
PMSF 1mM (added freshly) 
 
LiCl wash buffer 
0.25 M LiCl 
0.5 % NP-40 
0.5 % DOC 
1 mM EDTA 
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10 mM Tris-HCl, pH 8.0 
PIC 1:500 (added freshly) 
PMSF 1mM (added freshly) 
 
Elution buffer 
50 mM Tris-HCl, pH 8.0 
1 % SDS 
10 mM EDTA 
 
2.1.6.5 Buffers for flow cytometry (FACS) 
 
Sodium citrate                            
38 mM in 1X PBS  
 
2.1.6.6 Buffers for immunofluorescence  
PSP 
15 g paraformaldehyde 
10 g sucrose 
add to 500 ml in 1X PBS, stored at -20ºC 
       
PBST 
0.1 % Triton-X-100 
500 ml 1X PBS, stored at 4ºC 
and  
0.2 % Triton-X-100 
500 ml 1X PBS, stored at 4ºC 
 
Blocking solution 
5 % BSA in 1X PBS 
 
 
2.1.6.7 Buffers for centromere Fluorescence in-situ hybridization (FISH) 
 
Wash buffer I 
0.4X SSC 
0.3 % NP-40 
 
Wash buffer II 
2X SSC 
0.1 % NP-40 
 
 
2.1.6.8 Staining solution 
 
Crystal violet 
0.1 % crystal violet in 20 % ethanol 
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2.1.7 Antibodies 
 
2.1.7.1 Primary antibodies !!
Antibody 
against 
Catalog 
number Origin 
Application 
and dilution Company 
α-tubulin T6074 Mouse 
monoclonal 
WB 1:10,000 
IF 1:200 
Sigma 
Aurora B ab2254 Rabbit 
polyclonal 
WB 1:1000 Abcam 
β-actin sc-47778 Mouse 
monoclonal 
WB 1:5000 Santa Cruz 
B-Myb 
(LX015.1) none 
Mouse 
monoclonal 
WB 1:5 (Tavner et al., 2007) 
BrdU-FITC 347583 Mouse 
monoclonal 
IF 1:10 BD Bioscience 
Cyclin-A 
(BF683) sc-239 
Mouse 
monoclonal WB 1:1000 Santa Cruz 
E2F-1 (C-20) sc-193 Rabbit polyclonal WB 1:1000 Santa Cruz 
HA MMA-101P Mouse monoclonal 
WB 1:1000 
IF 1:100 
HISS 
IgG I5006 Mouse 
monoclonal 
ChIP 2 µg Sigma 
p21 (C-19) sc-397 Rabbit 
polyclonal 
WB 1:1000 Santa Cruz 
p27 610241 Mouse 
monoclonal 
WB 1:1000 
BD 
Transduction 
LaboratoriesTM 
p38 #9212 Rabbit 
monoclonal 
WB 1:1000 Cell signaling 
p53 (DO-1) sc-126 Mouse 
monoclonal 
WB 1:5000 
ChIP 3 µg 
Santa Cruz 
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pH3 06-570 Rabbit 
polyclonal 
WB 1:1000 Millipore 
Phospho-
ATM/ATR 
substrates 
#2851 
 
Rabbit 
monoclonal WB 1:1000 Cell signaling 
Phospho-Chk1 
(Ser345) #2348 
Rabbit 
monoclonal WB 1:1000 Cell signaling 
Phospho-Chk2 
(Thr68) #2661 
Rabbit 
monoclonal WB 1:1000 Cell signaling 
Phosho-Histone 
H2A.X (Ser139) #2577 
Rabbit 
monoclonal 
WB 1:1000 Cell signaling 
Phospho-p38 #4511 
 
Rabbit 
monoclonal 
WB 1:1000 Cell signaling 
Phospho-Ser2-
RNA 
Polymerase II 
ab5095 
 
Rabbit 
polyclonal ChIP 3 µg Abcam 
pRb sc-50 
 
Rabbit 
polyclonal 
WB 1:1000 Santa Cruz 
RNA 
Polymerase II 
sc-899 
 
Rabbit 
polyclonal 
ChIP 3 µg Santa Cruz 
SV40 Large T 
(Pab 108) 
sc-148 
 
Mouse 
monoclonal WB 1:1000 Santa Cruz 
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2.1.7.2 Secondary antibodies 
 
Antibody Company Application and dilution 
anti-mouse HRP 
conjugated GE Healthcare WB 1:5000 
anti-Protein A HRP 
conjugated BD Biosciences WB 1:5000 
anti-rabbit HRP conjugated Invitrogen WB 1:5000 
anti-mouse Alexa 488 Invitrogen IF 1:500 
anti-rabbit Alexa 594 Invitrogen IF 1:500 
 
 
2.1.8 Beads 
 
Dynabeads Protein G                                                               Life Technologies 
Monoclonal Anti-HA Agarose Conjugate Clone HA-7              Sigma 
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2.1.9 Plasmids 
 
2.1.9.1 Plasmids for overexpression 
 
Internal 
number Plasmid name Description 
210 pBabe-puro Empty vector control for retroviral transfections 
746 pBabe-H2B-GFP GFP control for retroviral transfections 
934 pBabe-puro-LargeT antigen-WT 
Retroviral expression of Large T antigen 
(wild type) 
1277 pBabe-puro-HA-p38alpha Retroviral expression of HA-p38alpha 
1279 pBabe-puro-HA-p38beta Retroviral expression of HA-p38beta 
1399 pBabe-puro-HA-mElongin A Retroviral expression of mouse Elongin A 
1400 pBabe-puro-LargeT-K1 mutant 
Retroviral expression of Large T K1 
mutant 
1401 pBabe-puro-LargeT-Δ434-444 mutant 
Retroviral expression of Large T Δ434-
444 mutant 
 
 
2.1.9.2 Plasmids for RNA knockdown 
 
Internal 
number Plasmid name Description 
652 pMSCV480-Blasticidin Empty vector control for retroviral transfections 
679 pMSCV480-shp53-Blasticidin Retroviral expression of shp53 
 
 
2.1.10 Primers 
 
Primer oligonucleotides were purchased from Metabion or MWG. 
 
2.1.10.1 Primers for cloning !
Internal 
number Sequence (5’ to 3’) Target gene Directionality 
SG1785 ggggatccATGGCGGCGGAGTC 
Mouse Elongin A 
Forward 
SG1786 gggctcgagTTATCGCCGGGAGAATC Reverse 
 
Restriction sites (BamHI GGATCC / XhoI CTCGAG) are underlined. 
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2.1.10.2 Primers for quantitative real time PCR 
 
All primers are for human sequences, unless indicated. 
 
Internal 
number Sequence (5’ to 3’) Target gene Directionality 
SG572 GGTACTGAAGTCCGGGAACC 
CCNA2 
Forward 
SG573 GAAGATCCTTAAGGGGTGCAA Reverse 
SG628 TCACTGTCTTGTACCCTTGTGC 
p21 
Forward 
SG629 GGCGTTTGGAGTGGTAGAAA Reverse 
SG645 GCCCAATACGACCAAATCC 
GAPDH 
Forward 
SG646 AGCCACATCGCTCAGACAC Reverse 
SG771 AGGCCTTGGAACTCAAGGAT 
p53 
Forward 
SG772 CCCTTTTTGGACTTCAGGTG Reverse 
SG1511 GACTCCAAGCGCGAAAAC 
MDM2 
Forward 
SG1512 GGTGGTTACAGCACCATCAGT Reverse 
SG1630 GATGGCCCAGAAGGAGAACT 
Aurora B 
Forward 
SG1631 AGGCTCTTTCCGGAGGACT Reverse 
SG1632 CAGTTCTGCTCTAGGTGGAAGTC 
TNFSF7 
Forward 
SG1633 AGGAAGAAGCGTTCGAGAGA Reverse 
SG1634 TTTGCCATCCAGAACAAGC 
ATF3 
Forward 
SG1635 CATCTTCTTCAGGGGCTACCT Reverse 
SG1636 AGAGGAGGAAAGGCAATGAAG 
SORC3 
Forward 
SG1637 TTGGTTGAGAGCATTAAACAGTG Reverse 
SG1638 GGGCCGTTACCCCTACATTA 
SESN1 
Forward 
SG1639 TTCACTAAGTAGGAGCACTG Reverse 
SG1648 TACTGACCCCACCTGAGCA 
FDXR 
Forward 
SG1649 TCGACTCTGCCTCAGTACACC Reverse 
SG1650 AAGGCACCTCTGAGAACTTCA 
SERPINE1 
Forward 
SG1651 CCCAGGACTAGGCAGGTG Reverse 
SG1652 TTCACCCAAGTGGTGCAG 
ANK1 
Forward 
SG1653 CTCATCCGTGAATTGCTCCT Reverse 
SG1656 CCGGATACTCACGCCAGA 
GDF15 
Forward 
SG1657 AGAGATACGCAGGTGCAGGT Reverse 
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SG1662 TTCCGTCCGCTAGGAGTCT 
BLM 
Forward 
SG1663 GACGTTCTAGTTGCTCCTGTAGATT Reverse 
SG1666 CGACGTTATTCTGATCTCACCA 
MCM3 
Forward 
SG1667 CAAGGGGATTGTTCTCCTCA Reverse 
SG1668 AGTAGGTGCTTGGCGGTTC 
RFC3 
Forward 
SG1669 CACAGTAGATAACACGTGGCAAA Reverse 
 !
2.1.10.3 Primers for Chromatin Immunoprecipitation 
 
 
 !! !
Internal 
number Sequence (5’ to 3’) Target Directionality 
SG540 GGCAGCAAGAGTCACTCCA GAPDH2 
promoter 
Forward 
SG541 TGTCTCTTGAAGCACACAGGTT Reverse 
SG1585 CTGTGGCTCTGATTGGCTTT p53 binding 
site 1 (p21 
promoter) 
Forward 
SG1586 CTCCTACCATCCCCTTCCTC Reverse 
SG1670 TATATCAGGGCCGCGCTG 
p21 gene (-20) 
Forward 
SG1671 GGCTCCACAAGGAACTGACTTC Reverse 
SG1672 CCAGGAAGGGCGAGGAAA p21 gene 
(+507), p21 
primary 
transcript 
Forward 
SG1673 GGGACCGATCCTAGACGAACTT Reverse 
SG1675 CGTGTTCGCGGGTGTGT p21 gene 
(+182) 
Forward 
SG1676 CATTCACCTGCCGCAGAAA Reverse 
SG1677 CCTCCCACAATGCTGAATATACAG p21 gene 
(+8566) 
Forward 
SG1678 AGTCACTAAGAATCATTTATTGAGCACC Reverse 
SG1679 CCTGGCTGACTTCTGCTGTCT p21 gene 
(+7011), p21 
primary 
transcript 
Forward 
SG1680 CGGCGTTTGGAGTGGTAGA Reverse 
SG1683 TCTGTCTCGGCAGCTGACAT p21 gene 
(+11443) 
Forward 
SG1684 ACCACAAAAGATCAAGGTGAGTGA Reverse 
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2.1.11 siRNA sequences 
 
siRNA oligos were purchased from MWG. !
siRNA 
against Sequence (5’ to 3’) Target/Reference 
ctrl UGGUUUACAUGUCGACUAA non targeting 
Aurora B AACGCGGCACUUCACAAUUGA Human Aurora B, Lampson et al., 2005 
pRb Dharmacon smart pool Human Retinoblastoma protein 
 
 
2.1.12 Cell lines, cell culture media and transfection reagents 
 
2.1.12.1 Media and additives for mammalian cell culture  
DMEM (4.5 g Glucose/L-Glutamine)  Gibco®, Life Technologies 
Fetal calf serum (FCS)  Gibco®, Life Technologies 
OptimeM  Gibco®, Life Technologies 
Penicillin/Streptomycin (10 U/µl each)  Cambrex/ Lonza 
TrpLETM  Express Gibco®, Life Technologies 
Trypsin EDTA (200 mg/ml)  Gibco®, Life Technologies 
 
 
2.1.12.2 Composition of media for soft agar assay 
 
10X DMEM (20 % FCS) (50 ml) 
10X DMEM   10ml 
1 M Sodium bicarbonate,  
autoclaved  1.85 ml (3.7 %) 
FCS   10 ml (20 %) 
200 mM Glutamax   5 ml (20 mM) 
D-gluc (dehydrated)   450 mg 
Penstrep   0.5 ml 
H2O   22.65 ml 
 
1.4 % low melting agarose, autoclaved  for base layer 
 
0.7 % low melting agarose, autoclaved  for top layer 
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2.1.12.3 Human cell lines and media 
 
All cell lines were cultured in DMEM media with 10 % FCS and 1 % Penstrep. 
 
Cell line Description Reference 
HCT116-
WT 
Human colorectal carcinoma tumor 
cell line (wild type p53 and p21) (Brattain et al. 1981) 
HCT116-
p21-/- 
Human colorectal carcinoma tumor 
cell line (p21 null) (Waldman et al. 1995) 
HCT116-
p53-/- 
Human colorectal carcinoma tumor 
cell line (p53 null) (Bunz, 1998) 
PlatE 
Retroviral packaging cell line for 
generating stable cell lines by 
retroviral infection 
(Morita et al. 2000) 
U2OS Human osteosarcoma tumor cell line (Ponten and Saksela 1967) 
U2OS-
EcoR-neo 
U2OS cells with ecotropic receptor 
for retroviral infection (neomycin 
resistance cassette) 
Created in lab by stably 
expressing ecotropic receptor 
(neomycin resistance) in U2OS 
cells 
 
 
2.1.12.4 Transfection reagents and cell lines 
 
Transfection reagent Cell line Purpose 
Lipofectamine RNAi Max U2OS siRNA transfection 
Calcium phosphate  U2OS Plasmid transfection 
Calcium phosphate PlatE Plasmid transfection 
 
 
2.1.12.5 Bacterial strains  
E.coli DH5α- competent cells for transformation of plasmid DNA 
 
2.1.12.6 Media for bacterial cell culture 
 
Luria Bertani (LB) Agar   40 g powder in 1 l H2O, autoclaved 
Luria Bertani (LB) Medium   25 g powder in 1 l H2O, autoclaved 
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2.2 Methods 
 
2.2.1 Mammalian cell culture 
 
2.2.1.1 Passaging of cells !
Eukaryotic cells were cultivated in a tissue culture incubator at 37ºC with 5 % CO2. For 
passaging, cells were washed once with PBS and incubated with TrypLE Express 
(HCT116-WT, p21-/-, p53-/- cells) or Trypsin/EDTA (U2OS and PlatE cells) for a few 
minutes at 37ºC. The detached cells were resuspended in media and plated on new cell 
culture dishes. 
2.2.1.2 Freezing and thawing of cells !
To freeze cells, cells on 10 cm dishes were trypsinized and transferred into a 15 ml falcon 
tube with 10 ml fresh media. Cells were then pelleted by centrifugation for 3 min at 1200 
rpm, the supernatant was discarded and the cells were resuspended in 1 ml ice-cold 
freeze medium (DMEM media containing 10 % DMSO) and transferred into cryotubes. 
Cells were stored at -80ºC for short term or in liquid nitrogen for long term. 
For thawing cells, cells were quickly thawed in a 37ºC water bath. The cell suspension 
was mixed with 9 ml fresh medium and centrifuged for 3 min at 1200rpm. The supernatant 
was discarded and the pellet was resuspended in 10 ml fresh medium and seeded into 10 
cm dishes. 
2.2.1.3 Counting cells !
Cell counting was performed using a Neubauer Chamber. The number of cells per ml in 
suspension was calculated using the following formula: 
Cells/ml = (Cells counted/ number of counted large squares) x 104   
2.2.1.4 Treatment of cells with reagents !
All treatments were done 24 h after seeding the cells. Before treatment, the cells were fed 
with fresh media. 
AMPK activator  Cells were treated with 200 µM AICAR for various time 
points. 
ATM kinase inhibitor  Cells were pretreated with 5 µM or 10 µM KU5593 for 2 h 
before any further treatments. 
ATR kinase inhibitor  Cells were pretreated with 0.1 µM or 1 µM VE821 for 2 h 
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before any further treatments. 
Aurora kinase inhibitors  Cells were treated with various concentrations of ZM447439 
or AZD1152-HQPA for different time points. 
BrdU  To label cells in S-phase cells were treated with 15 µg/ml 
BrdU for 2 h before fixation.  
Doxorubicin  To induce DNA damage cells were treated with 1 µM 
Doxorubicin for 6 h or 24 h. 
Hsp90 inhibitor  Cells were treated with 8 nM 17AAG for various time points. 
p38 MAP kinase inhibitors  Cells were pretreated with 10 µM SB202190 or 1 µM 
BIRB796 for 2 h before any further treatments. 
Thymidine  For cell synchronization in G1/S phase, cells were treated 
with 2.5 mM thymidine for 24 h. 
 
2.2.1.5 Synchronization of U2OS cells by thymidine !
For synchronization at the G1/S border, U2OS cells at 50 % confluency (seeded 24 h 
before) were treated with 2.5 mM thymidine for 24 h. Then, the cells were released into 
cell cycle by washing three times with PBS and feeding with fresh media. 
2.2.1.6 Determination of cell cycle phases by Flow Cytometry !
Cells in different cell cycle phases were measured by propidium iodide FACS (PI FACS). 
For this, cells were harvested by trypsinization and centrifuged at 1200 rpm for 5 minutes 
at 4ºC. Then, the pellet was washed once with ice cold PBS and the cells were fixed over 
night in 1 ml 80 % ethanol at -20ºC. Before measurement, cells were pelleted by 
centrifuging for 10 minutes at 1000 rpm followed by washing once with PBS at 4ºC. The 
cells were then resuspended in 500 µl 38 mM sodium citrate and 25 µl RNAse A (10 
mg/ml) for 1 h at 37ºC.  After this, the cells were stained with 15 µl PI (1 mg/ml) and then 
measured by FACS. 
2.2.1.7 Transient transfection !
2.2.1.7.1 Plasmid transfection with Calcium phosphate  !
PlatE cells were transfected using calcium phosphate. 30 µg of plasmid DNA was mixed 
with 50 µl of 2.5 M CaCl2 and with H2O to a final volume of 500 µl. In a 15 ml falcon tube, 
DNA/CaCl2 mixture was added drop wise to 500 µl of 2X HBS. This solution was added 
slowly to the cells. After 18-24 h of incubation, cells were washed once with PBS and fed 
with fresh medium. 24 hours later, the virus supernatant produced was harvested for cell 
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infection (see section 2.2.1.6). 
2.2.1.7.2 siRNA transfection with Lipofectamine RNAi Max !
U2OS cells were transfected with 10-45 nM siRNA using Lipofectamine RNAi Max (Life 
Technologies). Before starting, cells (seeded 24 h before) were fed with fresh media 
without penicillin and streptomycin. siRNA was diluted in Optimem to a final volume of 250 
µl (for 6 well) or 500 µl (for 6 cm dishes), mixed gently by pipetting once up and down and 
incubated for 5 minutes. In a separate tube, 2.5 µl Lipofecatime RNAi Max was diluted in 
OptimeM medium to a final volume of 250 µl (for 6 well), mixed gently by pipetting once 
up and down and incubated for 5 minutes (for 6 cm dishes 5 µl Lipofectamine RNAi Max 
was diluted to a final volume of 500 µl).  Then, the siRNA/OptimeM mix was added gently 
to Lipofectamine RNAi Max/OptimeM mix, and mixed gently by pipetting once up and 
down. This complex was incubated for 20 minutes and then added gently dropwise to 
cells. After 24 h, cells were fed with fresh media. The cells were harvested after 48-72 h of 
transfection, and processed for RNA or protein analysis. 
2.2.1.8 Retroviral infection of cells !
For production of ecotropic viral supernatant, platE cells were transiently transfected with 
the plasmid of interest using calcium phosphate (see section 2.2.1.5.1). 36-48 h after 
transfection, the virus supernatants were harvested, filtered (0.45 µm pore size), mixed 
with 10 µg/ml polybrene and added to the cells (U2OS-EcoR cells seeded 18-20 h 
before). 24 h after infection, the cells were washed once with PBS and fed with fresh 
medium and selection was started 48 h after infection. 
2.2.1.9 Immunofluorescence staining !
For immunofluorescence staining, cells were plated on cover slips in 6-well plates. After 
washing once with PBS cells were fixed with PSP for 10 min at RT. Cells were then 
washed twice with PBS, permeabilized in PBS/0.2 % Triton-X-100 for 5 min at RT and 
washed once in PBS/0.1 % Triton-X-100 (PBST). Unspecific staining was minimized by 
blocking for 30 min with 3 % BSA (in PBS). The cells were washed 3 times in PBS (p21-
staining) or 5 mM MgSO4 (in PBS for BrdU-staining) and incubated with the primary 
antibody diluted in PBS or 5mM MgSO4 (in PBS with DNAase for BrdU staining) for 1 h in 
a humidified chamber. The coverslips were then washed three times (3 minutes each) 
with PBS and incubated with the secondary antibody for 30 min in a humidified chamber. 
After washing with PBS for 3 times (3 minutes each) cells were stained with Hoechst 
33258 (1:1000 in PBS) for 1 minute, washed once with PBS and mounted on glass slides 
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with ImmuMount. 
2.2.1.10 ROS detection !
For the detection of ROS (reactive oxygen species), cells grown on coverslips were 
washed once with warm PBS and incubated with 10 µM 2'-7'-dichlorodihydrofluorescein 
diacetate (H2DCF-DA, Molecular Probes) in PBS. After 10 minutes at 37°C, the H2DCF-
DA solution was removed and the cells were incubated for 10 minutes with complete 
medium at 37°C. Cells were washed again with warm PBS and fixed in 4 % formalin. 
Nuclei were counterstained with Hoechst 33258. For detection with MitoSox Red, cells 
grown on coverslips were washed once with warm PBS and incubated for 10 minutes with 
5 µM MitoSox Red (Molecular Probes) in PBS at 37°C. Cells were washed three times 
with PBS and nuclei were counterstained with Hoechst 33342 for 20 minutes. The 
coverslips were then washed once with PBS and mounted on glass slides. Intracellular 
ROS levels were visualized using an inverted microscope.  
2.2.1.11 Centromere fluorescence in situ hybridisation (FISH) !
Cells were trypsinized and centrifuged for 3 minutes at 1000 rpm at room temperature. 
The cell pellet was resuspended in 5 ml 0.8 % sodium citrate and incubated at 37ºC for 30 
min. After a further centrifugation step of 3 minutes at 1000 rpm at room temperature, 
cells were fixed in 5 ml 3:1 methanol:glacial acetic acid solution (freshly prepared) and 
stored O/N at -20ºC. The fixed cells were dropped onto a slide and air-dried for 3 days (or 
at least for 24 h). After this, the sample slides were pretreated in 2X SSC/0.5 % NP-40 pH 
7.0 at 37ºC for minutes and then dehydrated in 70 %, 85 %, and 100 % ethanol for 1 
minute each. Then the slides were left to air dry at least for 30 minutes. After this 5µl of 
probe [5X, SE7(D7Z1)/8(D8Z1), Kreatech] against chromosome 7 (red) and chromosome 
8 (green) was applied, covered with glass coverslip, sealed with fixogum and left in dark 
for 2 minutes. Then the sample and probe were denatured on a hot plate at 75ºC for 5 
minutes in dark followed by overnight incubation at 37ºC in a humidified chamber in dark. 
The next day, after removing the coverslips the slides were first washed in preheated 
wash buffer I at 72ºC for 2 min, then washed in wash buffer II at room temperature for 1 
minute. After a dehydration series (70 %, 85 %, 100 % ethanol) for 1 min each, slides 
were air dried and then counterstained with DAPI, and covered with coverslip. 
2.2.1.12 Colony forming assay !
U2OS and HCT116-WT cells were plated in a very low density on 10 cm dishes (6000 
cells) or 6 well plates (700 cells/well) and treated with different drugs (ZM447439, 
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SB202190, AICAR, 17AAG). The cells were fed with fresh media and drug every 3 days. 
After 14 days, cells were fixed for 10 min with 4 % PFA, washed with tap water and air-
dried. Then the cells were stained with 0.1 % crystal violet staining solution for 20 min, 
washed with tap water and air dried again.  
For quantification, the crystal violet stain was extracted with 5 ml 10 % acetic acid by 
shaking for 20 minutes at room temperature. Then the extracted dye was diluted 1:4 in 
dH2O and absorbance was measured at 590 nm (using 10 % acetic acid as reference). 
 
2.2.1.13 Soft agar assay !
HCT116 cells seeded in 6 cm dishes were treated with ZM447439 and AICAR. Three 
days later, 1x104 cells were transferred to 2 ml DMEM containing 0.35 % low-gelling 
agarose (containing the respective drugs) and seeded in triplicate into six-well plates 
containing a 2-ml layer of solidified 0.7 % agarose in complete medium. After 13 days, the 
number of foci was scored. 
 
2.2.2 Molecular methods !
2.2.2.1 RNA isolation !
Total RNA was isolated from cells by using the RNA isolation reagent Trizol/Trifast 
(Peqlab). After removing the medium, 1 ml Trifast was added onto the cell culture plate 
and cells were collected into an eppendorf tube by pippeting up and down. After 5 minutes 
of incubation at room temperature, 200 µl chloroform was added and thoroughly vortexed 
for 15 sec and further incubated for 3 minutes at room temperature. Then the tubes were 
centrifuged at 12000 g and 4ºC for 10 min and the upper aqueous phase was transferred 
to a new reaction tube. RNA was precipitated with 500 µl isopropanol at -20ºC for 1 h and 
then centrifuged for 10 min at 12000 g and 4ºC. The pellet was washed with 75 % ethanol 
(in DEPC water) and resuspended in 25 µl DEPC water. 
2.2.2.2 Reverse transcription (RT) !
To transcribe RNA into cDNA, 2-2.5 µg RNA was mixed with 0.5 µg random primer (0.5 
mg/ ml) and brought to 10 µl with DEPC water. After incubation at 70ºC for 5 minutes, the 
samples were left for 1 min at 4ºC and then mixed with 5 µl M-MLV 5X reaction buffer, 
6.25 µl dNTPs (2 mM), 0.5 µl Ribolock RNase inhibitor (40 U/µl), 0.5 µl M-MLV-RT (200 U 
/µl) and 2.75 µl H2O. For cDNA synthesis, the samples were incubated at 37ºC for 60 min 
and then inactivated for 15 min at 70ºC. 
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2.2.2.3 Quantitative real-time PCR (qRT-PCR) !
To determine the amount of a specific mRNA compared to a housekeeping gene, the 
following reaction was prepared: 
Standard reaction mix: 
12.5 µl absolute qRT-PCR SYBER Green Mix  
10.5 µl H2O 
1 µl fw / rev primer mix (10 pmol/µl each)  
1 µl cDNA 
Standard PCR program (40 cycles): 
95 °C 15 min  
95 °C 15 s  
60 °C 1 min 
The relative expression of a gene compared to a housekeeping gene was calculated with 
this formula: 2-ΔΔCt 
where ΔΔCt = ΔCt (sample) – ΔCt (reference)  
and ΔCt = Ct (gene of interest) – Ct (housekeeping gene) 
The standard deviation of ΔΔCt was calculated with:  
s=√(s12+s22) 
where s1 = standard deviation (gene of interest)  
and s2 = standard deviation (housekeeping gene) 
The margin of error for 2-ΔΔCt was determined by this formula: 2-ΔΔCt+/-s and the error used 
for the error bars was calculated with: 2-ΔΔCt+/-s - 2-ΔΔCt 
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2.2.3 Biochemical methods  !
2.2.3.1 Whole cell lysates !
Cells were scraped with cold PBS and centrifuged for 5 min at 3000 rpm and 4°C. The 
pellet was resuspended with 10 times its amount of TNN buffer (with freshly added 
protease inhbitor cocktail in 1:1000 ratio) by vortexing and incubating on ice for 20 
minutes. Then the lysates were centrifuged at 14000 rpm for 10 min at 4ºC to remove cell 
debris. The supernatant was transferred in a new reaction tube and protein was quantified 
by Bradford method (see section 2.2.3.2). The required amount of protein was 
immediately used for immunoprecipitation (see section 2.2.3.3) or boiled with 3X ESB and 
loaded on SDS-polyacrylamide gel for SDS-PAGE (see section 2.2.3.4). Rest of the lysate 
was stored at -80ºC. 
2.2.3.2 Quantification of protein by Bradford method !
The protein concentration was determined with the method described by Bradford 
(Bradford, 1976). 1 µl of whole cell lysate was mixed with 100 µl 0.15 M NaCl and 1 ml of 
Bradford solution. Extinction at 595 nm was measured and compared to a standard BSA 
dilution series. 
2.2.3.3 Immunoprecipitation !
For immunoprecipitation, between 0.5 and 1 mg of whole cell lysate was incubated for 4 
hours or overnight, with the desired antibodies on a rotating wheel at 4°C. 40 µl of protein 
A- (polyclonal antibodies) or protein G-sepharose (monoclonal antibodies) were added 
and incubated for additional 1 h at 4 °C on the roating wheel. The beads were washed 5 
times with TNN and centrifuged between the washing steps for 1 minute at 3000 rpm at 
4°C. After the last wash, the supernatant was removed completely with a Hamilton syringe 
and the beads were resuspended in 40 µl 3X ESB and heated for 5 minutes at 95°C. 
Samples were stored at -20°C or directly used for electrophoresis. 
In parallel, 5-10 % of the protein amount used for immunoprecipitation was heated with 3X 
ESB at 95 °C for 5 min and used as input. 
 
2.2.3.4 SDS polyacrylamide gel electrophoresis (SDS-PAGE) !
SDS-PAGE analysis was performed using the discontinuous method (Laemmli, 1970). 8 - 
14 % resolving gel was prepared and after polymerization, the stacking gel was poured on 
the top. The gel compositions were as follows: 
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Separating gel (10 %)  Stacking gel 
6.1 ml H2O  6.9 ml H2O 
3.7 ml 1.5 M Tris pH 8.8  1.4 ml 0.5 MTris pH 6.8 
5 ml Acrylamid/Bisacrylamid  1.6 ml Acrylamid/Bisacrylamid 
75 µl 20 % SDS  50µl 20 % SDS 
100 µl 10 % APS  50µl 10 % APS 
10 µl TEMED  10 µl TEMED 
Electrophoresis was carried out in 1X SDS running buffer for about 1.5 h at constant 
current of 35 mA/gel. The gels were then used for immunoblotting. 
2.2.3.5 Immunoblotting !
The transfer of proteins onto PVDF membranes was done via electroblotting using a 
BioRad Wet Blot gadget. The PVDF membrane was preincubated for 1 min with 100 % 
methanol and rinsed with blotting buffer. The membrane was laid onto a layer of Whatman 
filter paper and the SDS-polyacrylamide gel was placed on the membrane, followed by a 
second layer of filter paper. This “sandwich” was clasped on both sides by sponges and 
placed in a cooled wet blotting tank (Biorad). The transfer was done for 1-2 h (depending 
on the size of the protein to be detected) at constant voltage of 100 V in 1X Blotting 
Buffer. Successful and equal transfer of proteins was visualized by staining of the 
membrane with a Ponceau S solution and destaining with H2O. 
To detect specific proteins with their respective antibodies, the membranes were blocked 
with 3 % milk powder in TBST (blocking solution) for 1 h, and then incubated overnight at 
4°C with the primary antibody diluted in blocking solution. Afterwards, the membrane was 
washed 3 times for 5 minutes in TBST and incubated with the secondary HRP- 
conjugated antibody (diluted in blocking solution) for 1 h at room temperature. After 3 
wash steps of 5 minutes in TBST, specific bands were detected using a Luminol-
substrate-solution. The membrane was wrapped in plastic foil and exposed to an ECL-
film. 
 
2.2.3.6 Chromatin immmunoprecipitation (ChIP) !
For ChIP, 4.5×106 cells were seeded in 15 cm dishes in 20 ml medium and 24 h later 
treated with various inhibitors. After 24 h, the cellular protein-DNA complexes were cross-
linked by adding 540 µl 37 % formaldehyde to the dishes and incubating at room 
temperature (slowly shaking) for 10 minutes. The reaction was stopped by adding 2.5 ml 1 
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M glycine and incubated for 5 minutes at room temperature. Afterwards cells were 
washed two times with ice cold PBS and scraped into 15 ml falcons and then pelleted by 
centrifugation at 1200 rpm for 5 minutes at 4ºC. The cells were lysed in 10 times lysis 
buffer (depending on the pellet) for 10 min. After centrifugation for 5 minutes, at 2800 rpm 
at 4ºC, the nuclei were lysed in 800 µl nuclei lysis buffer for 10 min. Lysed nuclei were 
sonicated for 10 min using the Bioruptor with 30 sec on/ 30 sec off cycle with high 
intensity. Thereby chromatin was fragmented into 250-1000 bp fragments. To remove cell 
debris chromatin was centrifuged at 14000 rpm for 10 minutes at 4ºC and 50 µl of the 
chromatin was used to check the chromatin size. For this, 2 µl of 5 M NaCl and 1 µl 
RNase A was added to the chromatin and incubated O/N at 65ºC. After 2 h treatment with 
2 µl Proteinase K (10 mg/ml) the chromatin size was analyzed on a 1.2 % agarose gel. 
The remaining chromatin was diluted 1:10 with dilution buffer and 2 ml chromatin was use 
per IP. 20 µl of the diluted chromatin was removed as input and stored overnight at -20ºC. 
After addition of the antibodies the samples were incubated at 4ºC overnight on a rotating 
wheel. The following day immunoprecipitations were collected by adding 50 µl magnetic 
Protein-G Dynabeads beads to the chromatin for 1-2 hours at 4ºC. The beads were 
washed 7 times with 1 ml LiCl-washing buffer and eluted with 100 µl elution buffer for 15 
min. A second elution step was performed with additional 150 µl elution buffer for 15 min 
and both supernatants were combined. To reverse the crosslinking, 10 µl 5 M NaCl and 5 
µl RNase A was added to the eluted chromatin as well to the input samples and incubated 
overnight at 65ºC. Proteins were degraded by incubation with 2 µl proteinase K (10 
mg/ml) for 2 h at 55ºC. Thereafter the DNA was purified using Qiagen PCR purification kit 
according to the manufacturers manual. The chromatin was eluted in 50 µl elution buffer 
(Qiagen). 
1 µl of the purified chromatin was used for quantitative PCR analysis and precipitated 
samples were compared to input chromatin. 
2.2.4 Molecular biology  !
2.2.4.1 Isolation of plasmid DNA from bacteria !
2.2.4.1.1 Mini preparation !
Single colonies were picked from an LB agar plate after transformation and incubated in 3 
ml LB medium containing ampicillin over night in a shaker at 37°C. 1.5 ml bacterial culture 
was pelleted and resuspended in 200 µl S1. The bacteria were lysed by adding 200 µl S2 
for 5 minutes. This reaction was neutralized with 200 µl S3. The bacterial debris was 
pelleted for 10 minutes at full speed at 4ºC and plasmid DNA in the supernatant was 
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precipitated with 500 µl isopropanol. After centrifugation for 20 minutes at 4ºC, the pellet 
was washed with 1 ml 70 % ethanol at 4ºC. The pellet was air dried and resuspended in 
50 µl H2O. Positive bacterial clones were identified by restriction digestion (see section 
2.2.4.4.4). 
2.2.4.1.2 Midi and Maxi preparation !
A single colony was picked from a LB agar plate after transformation and cultured in 3 ml 
LB medium containing ampicillin at 37 °C for 6-8 h. 500 µl of this culture was transferred 
into either 100 ml (Midi preparation) or 200 ml (Maxi preparation) LB medium containing 
ampicillin and left growing over night in a shaker at 37°C. Plasmids were purified with 
Midi- or Maxi-Kits from Invitrogen according to the manufacturer’s instructions. 
2.2.4.2 Isolation of plasmid DNA fragments from agarose gels !
Plasmid DNA was digested with the desired restriction enzymes and incubated at 37°C for 
1-2 h. The restriction digest was loaded on a 0.8 – 1.4 % agarose gel and fragments were 
separated by electrophoresis (see section 2.2.4.4.2) at 110 V for 1-2 h. The desired bands 
were cut out and isolated with the JetStar gel extraction kit (Genomed) according to the 
manufacturer’s instructions. 
2.2.4.3 Isolation of PCR products after restriction !
To purify PCR products after restriction digestion, the QIAquick PCR purification kit from 
Qiagen was used according to the manufacturer’s protocol. 
2.2.4.4 Standard cloning methods !
2.2.4.4.1 PCR for cloning of DNA fragments !
To amplify DNA fragments for cloning, the PhusionTM High Fidelity polymerase 
(Finnzymes) was used, which is a special proof reading polymerase and has a 3’- 5’ proof 
reading / exonuclease activity. 
Standard reaction mix: 
Template DNA  100 ng 
Polymerase buffer  10 µl 
Phusion polymerase  0.5 µl 
dNTPs (2mM)   5µl 
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Forward primer (10µM)  3µl   
Reverse primer (10µM)  3µl   
ddH2O  add to 50µl 
Standard PCR conditions: 
Initial denaturation  30 sec  98ºC 
Denaturation  10 sec  98ºC 
Annealing  30 sec  45-59ºC (primer dependent) 
Elongation  30 sec/kb  72°C → back to step 2, 30 cycles 72°C 
Final elongation  10 min  72ºC 
For further cloning, PCR products were separated on a 0.8-1.4 % agarose gel by 
electrophoresis (see section 2.2.4.4.2), excised and then eluted from the gel. Afterwards 
they were digested with the appropriate restriction enzymes (see section 2.2.4.4.3). 
2.2.4.4.2 Agarose gel electrophoresis !
DNA fragments from restriction digests (see section 2.2.4.4.3) or cloning PCRs (see 
section 2.2.4.4.1) were separated for analytical or preparative purpose via agarose gel 
electrophoresis. The desired amount of agarose (0.8 – 1.4 %) was added to 1X TAE 
buffer and then heated in a microwave until it was completely dissolved. Ethidium bromide 
was added in the concentration of 1 µg/100 ml to TAE to enable the visibility of the DNA 
fragments under UV light. DNA samples were mixed with 6X DNA-Loading buffer and 
loaded into the pockets of the gel. As a marker, 1 kb DNA ladder (Fermentas) was used. 
Electrophoresis was performed at 110 V for about 1-2 h. DNA bands were visualized 
under UV light and then photographed and/or excised. 
2.2.4.4.3 Restriction digestion !
Restriction digestion of plasmid DNA and PCR fragments was performed with an 
adequate restriction endonuclease and the recommended buffer for approximately 3 h at 
37°C. 
Standard reaction mix: 
DNA  0.5-5 µg  
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10X buffer  5 µl  
Enzyme  0.5 µl  
ddH2O  add to 50µl 
Digested DNA fragments from a vector were separated and analyzed by agarose gel 
electrophoresis. Digested PCR products were purified with the QIAquick PCR purification 
kit. 
2.2.4.4.4 Ligation !
Ligation was performed with T4-DNA-ligase (NEB) in a molar ratio of 1:3 and 1:5 (vector 
to insert). The mixture was set up in a 15 µl volume, with 1 unit T4-DNA-ligase and ~50 ng 
vector DNA and incubated at room temperature for 1 h. 5 µl of ligation mix was used for 
transformation (see section 2.2.4.4.5). 
2.2.4.4.5 Transformation of DH5α by heat shock !
For transformation, chemical competent bacteria cells (DH5α) were used. These cells 
(stored at -80°C) were first thawed on ice for 10 min. Then 100 ng of plasmid DNA or the 
5 µl ligation reaction were mixed with 60 µl of the bacteria in a reaction tube and the 
mixture was set on ice for 10 min. Next, the bacteria were given heat shock for 90 
seconds at 42°C and then cooled on ice for 3 minutes. After addition of 400 µl warm LB 
media (without antibiotics), the sample was incubated for 15-30 min at 37°C. The bacterial 
cells were centrifuged for 2 minutes at 1000 g and the supernatant was discarded. The 
pellet was resuspended in 50 µl LB medium and plated on LB agar plates (with required 
antibiotic) and incubated over night at 37°C. The colonies were picked for plasmid 
isolation. 
2.2.4.4.6 Sequencing !
All sequencing was done by LGC genomics
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3 Results 
 
3.1 Inhibition of Aurora B results in polyploidy and induction of the cell cycle 
inhibitor p21 
To investigate the effect of Aurora B inhibition on cell cycle progression, two chemical 
inhibitors of Aurora B kinase, ZM447439 (Ditchfield et al. 2003) and AZD1152-HQPA 
(Yang et al. 2007; Wilkinson et al. 2007) were used. In addition, Aurora B was also 
depleted by a specific siRNA. Further, two cell lines U2OS and HCT116 were employed 
for the study. 
 
3.1.1 Inhibition of Aurora B in U2OS cells results in polyploidy and induction 
of p21 
Given the critical requirement of Aurora B during cell cycle, impairment of its function is 
associated with polyploidy (Hauf 2003; Wilkinson et al. 2007; Ditchfield et al. 2003) and 
cell cycle arrest due to induction of the CDK inhibitor p21(Cip1) (Gizatullin et al. 2006; 
Trakala et al. 2013). Indeed these phenotypes were observed when Aurora B was 
inhibited in U2OS cells by ZM447439 (Fig. 10A and B). U2OS cells were treated with 
ZM447439 for 24 h and then processed for immunostaining to visualize nuclei and p21 
(Fig. 10A), which indicated that a large fraction of cells become multinucleated (indicating 
failure of cytokinesis) and show very strong p21 induction upon Aurora B inhibition. DNA 
content analysis of ZM447439 treated U2OS cells by flow cytometry (PI FACS) further 
confirmed the polyploidy status of these cells as compared to normal cell cycle profile of 
DMSO treated control cells (Fig. 10B). Absence of sub-G1 population in the PI FACS 
profile of ZM447439 treated cells (Fig. 10B) indicated that there was no apoptosis in 
U2OS cells after Aurora B inhibition. Also treatment of U2OS cells with a more specific 
Aurora B inhibitor AZD1152-HQPA (Mortlock et al. 2007) resulted in induction of p21 in 
time and concentration dependent manner, as shown by immunoblotting for p21 (Fig 
10C). To rule out the possibility that the observed cellular response is an artifact of 
pharmacological inhibition, Aurora B was depleted by a specific siRNA, which also 
resulted in strong induction of p21 protein (Fig. 10D). 
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Figure 10: Inhibition of Aurora B in U2OS cells results in polyploidy and induction of p21. 
(A) U2OS cells were treated with DMSO or 1 µM ZM447439 for 24 h. p21 (in red) and α-tubulin 
(in green) were detected by immunostaining. Nuclei (in blue) were stained with Hoechst 33528. 
(B) U2OS cells were treated as in (A) and analyzed by PI FACS. (C) U2OS cells were treated 
with DMSO or indicated concentrations of AZD1152-HQPA for 24 h or 48 h and p21 levels were 
determined by immunoblotting. β-actin served as loading control. (D) U2OS cells were 
transfected with indicated concentrations of control siRNA or Aurora B specific siRNA for 48 h. 
p21 and Aurora B levels were determined by immunoblotting. α-tubulin served as loading 
control. 
Parts of this figure were published in similar form in Kumari et al. 2013. 
 
3.1.2 Inhibition of Aurora B in HCT116 cells results in polyploidy and 
induction of p21 
To further confirm that the effects of Aurora B inhibition are not specific for one cell line, 
another cell line HCT116 was used. Treatment of HCT116 cells with ZM447439 or 
AZD1152-HQPA also resulted in induction of p21 protein in a time and concentration 
dependent manner (Fig. 11A). The flow cytometry profiles of HCT116 cells treated with 
two different Aurora B inhibitors also indicated generation of multinucleated cells (increase 
in proportion of cells with DNA content of 4N or more) (Fig 11B). The fraction of cells with 
4N DNA content increased after prolonged treatment for 48 h (as compared to 24 h) (Fig 
11B), indicating that some cells escaped arrest at 4N and continued through additional 
cell cycles, a phenotype of Aurora B inhibition shown previously (Ditchfield 2003; 
Gizatullin et al. 2006). These findings are in line with previous studies (Tao et al. 2008; 
Kaestner at al. 2009; Nair et al. 2009) and imply that p21 induction and generation of 
polyploidy is a general response to Aurora B inhibition and is not restricted to only one 
cancer cell type, confirming Aurora B as a key regulator of cell division. 
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Figure 11: Inhibition of Aurora B in HCT116 cells results in polyploidy and induction of 
p21. 
(A) HCT116 cells were treated with DMSO or with the indicated concentrations of ZM447439 or 
AZD1152-HQPA for 24 h or 48 h. p21 levels were determined by immunoblotting. β-actin served 
as loading control. (B) FACS analysis of HCT116 cells treated with DMSO, ZM447439 (0.5 µM 
or 1 µM) or AZD1152-HQPA (50 nM or 100 nM) for 24 h or 48 h.!!
This figure was published in similar form in Kumari et al. 2013.!
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3.2 Induction of p21 in response to Aurora B inhibition depends on p53 
Since p21 is a well-known p53 target gene (El-Deiry et al. 1993) and recent studies 
showed a role of Aurora B in mediating p53 degradation (Wu et al. 2011; Gully et al. 
2012), it was of considerable importance to test the requirement of p53 for p21 induction 
after Aurora B inhibition. Indeed strong induction of p53 was observed upon treatment of 
U2OS cells with Aurora B inhibitor ZM447439 (Fig. 12A). To test whether induction of p21 
is p53 dependent, HCT116 p53 null cells (Bunz, 1998) were used. Treatment of HCT116  
 
!!
Figure 12: Induction of p21 in response to Aurora B inhibition depends on p53. 
(A) U2OS cells were treated with DMSO or 1 µM ZM447439 for 24 h. p53 and p21 levels were 
determined by immunoblotting. β-actin served as loading control. (B) HCT116 wild type (WT) 
and p53 negative cells were treated with DMSO, 1 µM ZM447439 for 48 h or with 1 µM 
doxorubicin (Doxo) for 24 h. p53 and p21 levels were determined by immunoblotting. β-actin 
served as loading control. (C) U2OS-EcoR cells stably expressing empty vector (E.V.) or SV40-
Large T antigen (wild type, K1 or ∆434-444) were treated with DMSO or 1 µM ZM447439 for 24 
h. Large T and p21 levels were analyzed by immunoblotting. β-actin served as loading control. 
(D) U2OS cells were transfected with 12 nM control siRNA or pRb specific siRNA for 48 h and 
then treated with DMSO or 1 µM ZM447439 for 24 h. pRb and p21 protein levels were 
determined by immunoblotting. β-actin was used as loading control. 
Parts of this figure were published in similar form in Kumari et al. 2014. 
 
wild-type (WT) cells with ZM447439 or doxorubicin (a DNA damaging agent, used as 
positive control) activated p53 and induced p21, whereas ZM447439 and doxorubicin 
failed to induce p21 in isogenic HCT116 p53 null cells (Fig. 12B), indicating that p53 is 
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required for p21 induction in response to Aurora B inhibition. To further verify the 
requirement of p53 for p21 induction, U2OS-EcoR cells stably expressing the SV40 large 
T (LT) antigen that binds and inhibits pRb family members and p53 (Ali and DeCaprio 
2001), were generated. Two mutants of LT, LT-K1 and LT-Δ434-444, were also used to 
test which pathway (pRb or p53) is involved in p21 induction. The LT-K1 mutant can no 
longer bind to and inactivate pRb and thus only targets p53 (Stubdal et al. 1997). In 
contrast, LT-Δ434-444 cannot bind to p53 and only targets pRb and the related ‘pocket 
proteins’ p107 and p130 (Kierstead and Tevethia 1993). Expression of LT wild-type and 
its mutants was verified by immunoblotting (Fig. 12C). Expression of all three LT antigens 
was detectable and not changed after Aurora B inhibition, although expression of LT-
Δ434-444 was weaker as compared to LT-wild-type and LT-K1, as has been 
demonstrated previously (Ye et al. 2007) (Fig. 12C). Induction of p21 after inhibition of 
Aurora B was blocked by wild-type LT (Fig. 12C).  The K1 mutant was also able to block 
p21 induction, while LT-Δ434-444 did not prevent induction of p21 after Aurora B inhibition 
by ZM447439 treatment. However, since the LT-Δ434-444 mutant was expressed at low 
levels as compared to wild-type and K1 mutant, to directly test the requirement of pRb for 
p21 induction after Aurora B inhibition, pRb was knocked down by pRb specific siRNA 
(Fig. 12D). Knockdown of pRb had no effect on p21 induction after Aurora B inhibition 
(Fig. 12D). Taken together, these findings indicate that p53 but not pRb-proteins are 
required for induction of p21 in response to Aurora B inhibition. 
 
3.3 p38 MAPK is required for induction of p21 in response to Aurora B 
inhibition 
Cell cycle arrest by p53-p21 activation due to impairment of cytokinesis and resulting 
tetraploidy has been reported to involve the stress-activated kinase, p38 MAPK (Ganem 
and Pellman 2007; Mikule et al. 2007; Thompson and Compton 2010). Hence, it was of 
interest to investigate if p38 MAPK is involved in p21 activation in response to Aurora B 
inhibition. To test this, an antibody against the active phosphorylated form of p38 MAPK 
was used. Strikingly, p38 MAPK was phosphorylated and hence activated in a time 
dependent manner after Aurora B inhibition (Fig. 13A). The total p38 protein levels 
remained unchanged after treatment with ZM447439. There was a correlation in activation 
of p38, induction of p53 and activation of p21 in a time dependent manner after Aurora B 
inhibition, suggesting that inhibition of Aurora B could result in activation of p38-p53-p21 
pathway that blocks the proliferation of cells (Fig. 13A). The next important question to be 
addressed was whether p38 is required for activation of p53 and p21 in response to  
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Figure 13: p38 MAPK is required for induction of p21 in response to Aurora B inhibition.  
(A) U2OS cells were treated for the indicated timepoints with 1 µM ZM447439. Levels of p53, 
p21, phosphorylated p38 (p-p38), total p38 and α-tubulin (control) were determined by 
immunoblotting. (B) U2OS cells were treated with DMSO, 1 µM ZM447439 alone, 10 µM 
SB202190 alone or pretreated with 10 µM SB202190 for 2 h and then treated with 1 µM 
ZM447439 for 24 h. Levels of p21 and p53 were determined by immunoblotting. β-actin served 
as loading control. (C) U2OS cells were treated with DMSO, 50 nM AZD1152-HQPA alone, 1 µM 
BIRB796 alone or pretreated with 1 µM BIRB796 for 2h and then treated with 50 nM AZD1152-
HQPA for 24 h. Levels of p21 and p53 were determined by immunoblotting. β-actin served as 
loading control. (D) HCT116 cells were treated with DMSO, 1 µM ZM447439 alone, 1 µM 
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BIRB79 alone or pretreated with 1 µM BIRB796 for 2 h and then treated with ZM447439 (1 µM) 
for 24 h. p21 and p53 protein levels were determined by immunoblotting. β-actin served as 
loading control. (E) HCT116 cells were treated as in (D), but with a different Aurora B inhibitor, 
AZD1152-HQPA (50 nM). α-tubulin served as loading control. (F) U2OS cells were treated with 
DMSO, 1 µM ZM447439 alone, 10 µM SB202190 alone, 1 µM doxorubicin (Doxo) alone or pre-
treated with 10 µM SB202190 for 2 h, and then treated either with 1 µM ZM447439 or 1 µM 
doxorubicin (Doxo) for 24 h. Levels of p21 were determined by immunoblotting. β-actin served 
as loading control. 
This figure was published in similar form in Kumari et al. 2013. !
Aurora B inhibition. For this, two chemical inhibitors of p38 MAPK, SB202190 (inhibits all 
the four isoforms p38α, p38β, p38 γ and p38δ) (Lee et al. 1994) and BIRB796 (inhibits 
specifically p38α and p38β isoforms) (Kuma et al. 2005) were used. Co-treatment with 
SB202190 and ZM447439 blocked the p21 induction mediated by ZM447439 alone, 
indicating that indeed p38 is required for p21 induction after inhibition of Aurora B (Fig. 
13B). The other more specific p38 inhibitor BIRB796 also blocked the p21 induction 
mediated by AZD1152-HQPA (Fig. 13C) as well as ZM447439 (Fig. 13D and Fig 13E) in 
both U2OS and HCT116 cells, confirming that p38 signaling contributes to p21 induction. 
Interestingly inhibition of p38 (by SB202190 or BIRB796) did not affect p53 activation after 
Aurora B inhibition, suggesting that p53 induction does not require activation of p38 (Fig. 
13B, C, D, E). To test whether requirement of p38 MAPK was specific for the p21 
induction observed after Aurora B inhibition, cells were treated with the chemotherapeutic 
drug doxorubicin (a DNA damaging agent), which also induces p21 (Fig. 13E, lane 5). 
However, this p21 induction was not blocked by SB202190 co-treatment, indicating that 
p38 is not required for p21 activation following a different type of cellular stress, such as 
DNA damage. These results emphasize that p38 MAPK is specifically required for 
activation of p21 after impairment of Aurora B function. 
 
3.4 Co-inhibition of Aurora B and p38 inhibits cell proliferation in p53 
dependent manner 
Previous data from our group indicated that long-term co-treatment of cells with 
ZM447439 and SB202190 resulted in reduced colony formation due to apoptosis (data 
from Tanja Ulrich, published in Kumari et al. 2013). To investigate whether this 
cooperation requires p53, U2OS-EcoR cells stably expressing shRNA against p53 were 
generated. The knock down of p53 was confirmed by RT-qPCR of the RNA isolated from 
cells stably expressing shp53 (Fig. 14A). As a control, cells expressing empty vector were 
used. These cells were seeded at very low density (6000 cells/10 cm dish) and treated 
with DMSO, ZM447439 alone, SB202190 alone or a combination of ZM447439 and 
SB202190 for 14 days and then the colonies were visualized by crystal violet staining. 
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While a strong reduction in colony formation was observed in cells expressing empty 
vector upon combination of ZM447439 and SB202190 treatment, this co-operation was 
weaker in cells in which p53 was knocked down (Fig. 14B). In light of the previous finding 
from our group that SB2020190 co-operates with ZM447439 to inhibit colony formation by 
inducing apoptosis, this result supports that functional p53 is required for the induction of 
apoptosis when p38 is inhibited along with Aurora B. 
 
!
Figure 14: Co-inhibition of Aurora B and p38 inhibits cell proliferation in p53 dependent 
manner. 
(A) Quantification of p53 mRNA levels in U2OS-EcoR cells stably expressing empty vector (EV) 
or shRNA against p53 (shp53). (B) U2OS-EcoR cells stably expressing empty vector (EV) or 
shRNA against p53 (shp53) were treated with DMSO, 0.5 µM ZM447439 alone, 10 µM 
SB202190 alone or a combination of 0.5 µM ZM447439 and 10 µM SB202190 for 14 days. The 
colonies were fixed and stained with crystal violet. 
 
 
3.5 Cell cycle arrest after Aurora B inhibition requires p21 and is mediated 
by inhibition of E2F-dependent transcription 
To directly test the requirement of p21 in cell cycle arrest and hence preventing 
endoreduplication following Aurora B inhibition, HCT116 p21 null cells (Waldman et al. 
1995) were used. Upon treatment with ZM447439, the proportion of cells with 4N DNA 
content was significantly increased in HCT116 p21 null cells as compared to isogenic 
HCT116 wild-type (WT) cells, indicating that p21 prevents polyploidization after inhibition 
of Aurora B (Fig. 15A).  
To investigate if impairment of Aurora B function also regulates other genes besides p21, 
a genome-wide microarray analysis was performed in our group (performed by Tanja 
Ulrich and published in Kumari et al. 2014). For this, U2OS cells were treated with DMSO, 
ZM447439 alone, SB202190 alone or pretreated with SB202190 for 2 h and then treated 
with ZM447439 for 24 h. The results of this analysis indicated that in addition to a large 
number of genes, which were up regulated by 2-fold on ZM447439 treatment (730 genes) 
some genes were also down regulated (430 genes) by 2-fold. The expression of 53 %  
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Figure 15: Cell cycle arrest after Aurora B inhibition requires p21 and is mediated by 
inhibition of E2F-dependent transcription. 
(A) HCT116 wild type (WT) and HCT116 p21 null cells were treated with 1 µM ZM447439 for 24 
h and 48 h. Cell cycle distribution was analyzed by FACS. (B) U2OS cells were treated with 
DMSO, 1 µM ZM447439 alone, 10 µM SB202190 alone or pretreated with 10 µM SB202190 for 
2 h and then treated with 1 µM ZM447439 for 24 h. Levels of p21, hyperphosphorylated Rb (p-
!!
!
Results 
!
! !
53!
pRb) and hyphophosphorylated Rb (pRb) were determined by immunoblotting.  β-actin served 
as loading control. (C) U2OS cells were treated as described in (B) and mRNA levels of the 
indicated E2F-target genes were determined by RT-qPCR. (D) The indicated U2OS cell lines 
were treated with either DMSO or 1 µM ZM447439 for 24 h and flow cytometry was performed to 
determine the fraction of cell in the different phases of the cell cycle. 
Parts of this figure were published in similar form in Kumari et al. 2013 and Kumari et al. 2014. 
 
(220 genes) of these down-regulated genes was restored upon p38 co-inhibition by 
SB202190 treatment. Hence these genes required p38 for their expression and might be 
involved in cell cycle arrest upon Aurora B inhibition. Gene Ontology (GO) analysis of 
these down-regulated genes whose expression was restored upon p38 co-inhibition 
demonstrated that they play roles in DNA-replication and repair, cell cycle regulation and 
mitosis and that many of them are known targets of the pRb/E2F pathway. Owing to the 
fact that p21 is a CDK inhibitor (Harper et al. 1993; Sherr and Roberts 1995) and therefore 
indirectly inhibits phosphorylation of the retinoblastoma (pRb) proteins by CDKs (Heuvel 
and Dyson 2008; Dimova and Dyson 2005), we hypothesized that p21 induced as a result 
of Aurora B inhibition resulted in cell cycle arrest by indirect dephosphorylation of pRb, as 
phosphorylation of pRb is required for cell cycle progession. Expression of p21 thus 
results in repression of E2F-regulated genes through the formation of repressive pocket-
protein/ E2F complexes. To investigate whether phosphorylation of pRb is indeed 
inhibited after inhibition of Aurora B, the phosphorylation status of pRb was analyzed 
before and after treatment with ZM447439. Inhibition of Aurora B resulted in 
dephosphorylation of pRb (Fig. 15B) and this dephosphorylation of pRb was prevented by 
SB202190 co-treatment, indicating that p38 signaling is indeed required for formation of 
the active, repressive state of pocket-proteins via activation of p21, which in turn results in 
cell cycle arrest. This effect of p21 on pRb and hence the targets of pRb/E2F pathway, 
was further verified for some of the genes from microarray analysis. mRNA levels of E2F-
target genes BLM, RFC3 and MCM3 were down-regulated by ZM447439 and restored 
upon SB202190 co-treatment (Fig. 15C), suggesting that the cell cycle arrest after Aurora 
B inhibition requires E2F target genes.  Also, when pRb proteins were inhibited by 
expression of Large T antigen (wild type or its Δ434-444 mutant), the proportion of 
polyploid cells increased as compared to the control cells (expressing empty vector) upon 
ZM447439 treatment (Fig. 15D). Collectively these results suggest that inhibition of Aurora 
B leads to cell cycle arrest through p53 and p38-dependent p21 induction, pocket-protein 
dephosphorylation and inhibition of E2F-dependent transcription. !
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3.6 p38 MAPK is required for transcriptional induction of p21 but not for its 
protein stability 
To investigate if p38 has a role in transcription of the p21 gene in response to Aurora B 
inhibition, mRNA levels of p21 were analyzed by real time RT-qPCR. Treatment of cells 
with ZM447439 resulted in induction of p21 mRNA levels and this induction was blocked 
by SB202190 co-treatment (Fig. 16A), indicating that p21 transcriptional induction after 
Aurora B inhibition depends on p38 signaling. p38 has been reported to stabilize p21 by  
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Figure 16: p38 is required for transcriptional induction of p21 but not for its protein 
stability. 
(A) U2OS cells were treated with DMSO, 1 µM ZM447439 alone, 10 µM SB202190 alone or 
pretreated with 10 µM SB202190 for 2 h and then treated with 1 µM ZM447439 for 24 h. mRNA 
level of p21 was determined by RT-qPCR. (B) U2OS cells were treated with DMSO, 1 µM 
ZM447439 or pretreated with 10 µM SB202190 for 2 h followed by treatment with 1 µM 
ZM447439 for 22 h and then with 20 µg/ml cycloheximide (CHX) for the indicated time points to 
block protein synthesis. p21 levels were determined by immunoblotting. β-actin served as loading 
control. (C) The protein bands of p21 and β-actin of the blot shown in (B) were quantified by 
ImageJ. The amount of p21 protein (relative to β-actin) was plotted against time. 
Parts of this figure were published in similar form in Kumari et al. 2013. 
 
phosphorylating it at Ser-130 in response to stress signals induced by TGFβ (Kim et al. 
2002). To examine if p38 activated as a consequence of Aurora B inhibition has an effect 
on p21 protein stability, the half-life of p21 protein induced after Aurora B inhibition (in 
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absence and presence of p38 co-inhibition) was determined by using cycloheximide (a 
protein synthesis inhibitor). U2OS cells were treated with ZM447439 or pretreated with 
SB202190 for 2 hours followed by ZM447439 treatment for 22 hours and then either left 
untreated or were treated with cycloheximide for 0.5, 1 and 2 hours. The stability of p21 
protein induced after Aurora B inhibition was not affected by co-inhibition of p38, 
indicating that p38 does not influence p21 protein stability under these conditions (Fig. 
3.6B). 
 
3.7 p38 MAPK is not required for p53 binding to p21 promoter in response to 
Aurora B inhibition 
Having shown that p38 is required for transcriptional induction of p21 without affecting its 
protein stability and total p53 protein levels; it was tempting to study the transcriptional 
regulation of p21 gene in more detail. For this, first the binding of p53 to the p21 promoter 
was studied by chromatin immunoprecipitation (ChIP) assay at p21 gene locus using an 
antibody specific for p53. Cells were treated with DMSO, ZM447439 or with a combination 
of SB202190 (pretreatment for 2 h) and ZM447439. Chromatin was isolated and 
immunoprecipitated with a p53 specific antibody. As a control, nonspecific IgG was used.  
Promoter regions were detected by quantitative real time PCR. p53 binding was robustly 
induced at the high affinity p53 binding site 1 (p53BS1) upon treatment with ZM447439 
(Fig. 17B) or AZD1152-HQPA (Fig. 17D).  No significant binding of p53 was observed at 
the distal regions of the p21 gene, as expected (Fig. 18B).  In addition, no significant 
binding was observed at the GAPDH2 promoter used as a control.  Interestingly, p53 
binding was not affected by p38 inhibition with SB202190 (Fig. 17B) or BIRB796 (Fig. 
17D). Thus, p38 is not required for binding of p53 to its binding site on p21 promoter, 
implicating that p38 acts at a step subsequent to p53 binding at the p21 gene locus. 
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Figure 17: p38 MAPK is not required for p53 binding to p21 promoter in response to 
Aurora B inhibition. 
(A) and (B) U2OS cells were treated with DMSO, 1 µM ZM447439 alone, or pretreated with 10 
µM SB202190 for 2 h and then treated with 1 µM ZM447439 for 24 h. Chromatin was isolated 
and precipitated with antibody specific for p53 or nonspecific IgG. ChIP enriched DNA was 
amplified by qPCR using the indicated amplicons. GAPDH2 promoter was analyzed as a control. 
(C) and (D) HCT116 cells were treated with DMSO, 50 nM AZD1152-HQPA alone, or pretreated 
with 1 µM BIRB796 for 2h and then treated with 50 nM AZD1152-HQPA for 24 h. Chromatin was 
isolated and precipitated with antibody specific for p53 or nonspecific IgG. ChIP enriched DNA 
was amplified by qPCR using the indicated amplicons. GAPDH2 promoter was analyzed as a 
control. 
 
3.8 p38 MAPK is required for transcriptional elongation of p21 in response to 
Aurora B inhibition 
Regulation of p21 expression has been shown to occur at the level of transcriptional 
elongation (Gomes et al. 2006; Valin et al. 2013). To explore this possibility, ChIP assay 
with antibody against RNA Polymerase II (RNA Pol II) was performed at the p21 gene 
locus. Significant amount of RNA Pol II was observed at the core promoter (-20 region) of 
p21 gene even before stimulation by inhibition of Aurora B (Fig. 18D), consistent with 
previous reports showing that RNA Polymerase II is paused at the promoters of stress 
responsive genes (Adelman and Lis 2012). Very low binding of RNA Pol II was observed 
in the transcribed region of the p21 gene, indicating that the polymerase is paused at the 
p21 promoter. Upon inhibition of Aurora B by ZM447439 treatment, loading of RNA Pol II  
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Figure 18: p38 MAPK is required for transcriptional elongation of p21 in response to 
Aurora B inhibition. 
(A) Schematic diagram of the p21 gene locus and position of the amplicons used for ChIP 
analysis and primary transcript analysis. U2OS cells were treated with DMSO, 1 µM ZM447439 
alone, or pretreated with 10 µM SB202190 for 2 h and then treated with 1 µM ZM447439 for 24 
h. Chromatin was isolated and precipitated with nonspecific IgG (B), antibody specific for p53 
(C), total RNA polymerase II (D) and phospho-ser2 RNA Pol II (E). ChIP enriched DNA was 
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amplified by qPCR using the indicated amplicons. The GAPDH2 promoter was analyzed as a 
control. (F) U2OS cells were treated with DMSO, 1 µM ZM447439 alone, or pretreated with 10 
µM SB202190 for 2 h and then treated with 1 µM ZM447439 for 24 h. Total RNA was isolated 
and subjected to RT-qPCR using primers specific for shorter (+507) and longer region (+7011) 
primary p21 transcripts. 
This figure was published in similar form in Kumari et al. 2013. 
 
moderately increased at the core promoter (less than 2-fold), whereas it’s loading in the 
distal regions of the p21 gene was strongly induced (3-4 fold) (Fig. 18D). The loading of 
RNA Pol II at the core promoter (-20 region) was not affected by p38 inhibition by 
SB202190 co-treatment (instead there was a slight increase binding), whereas its 
recruitment to the distal regions of the p21 gene was strongly blocked upon p38 inhibition 
(Fig. 18D). These findings indicate a role for p38 MAPK in mediating transcriptional 
elongation of p21 gene after recruitment of RNA Pol II, in response to Aurora B inhibition. 
To confirm the requirement of p38 in elongation stage of the transcriptional induction of 
p21, ChIP assay was performed with antibody against RNA polymerase II phosphorylated 
at serine 2 (Ser 2P RNA Pol II), which represents the elongating form of RNA Polymerase 
II (Phatnani and Greenleaf 2006; Egloff et al. 2012). Interestingly the elongating form of 
RNA polymerase II was strongly enriched towards the 3’ region of the p21 gene after 
Aurora B inhibition by ZM447439 and this enrichment was impaired by p38 inhibition by 
SB202190 co-treatment (Fig. 18E), emphasizing the notion that p38 is required for 
transcriptional elongation of p21 gene. To corroborate the finding that p38 is required for 
the elongation of the p21 gene and hence is required to generate the full-length p21 
mRNA, nascent p21 transcripts were analyzed by RT-qPCR. Short p21 transcripts were 
analyzed by with primers specific for an amplicon in the first intron of the gene (+507) 
whereas long p21 transcripts were analyzed with primers specific for the second intron 
just before the third exon (+7011). Inhibition of Aurora B by ZM447439 treatment induced 
short transcripts, but their induction was not prevented by co-inhibition of p38. Longer p21 
transcripts were also induced after Aurora B inhibition. Importantly, accumulation of the 
longer transcript was significantly reduced when p38 was inhibited by SB202190 co-
treatment (Fig. 18F). Together these data indicate that p38 signaling is required for 
transcriptional elongation of p21 after Aurora B inhibition. 
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3.9 Transcriptional elongation of p21 in response to replication stress is 
dependent on p38 MAPK 
Several studies have investigated the transcriptional elongation control of p21 in response 
to stress (Espinosa et al. 2003; Mattia et al. 2007; Beckerman et al. 2009; Gomes 2006; 
Valin et al. 2013). Beckerman et al. (2009) demonstrated that blocking DNA replication by 
hydroyxurea (HU, induces S-phase arrest by replication block) induced p53 but did not 
activate a subset of p53 targets including p21 due to marked reduction in its 
transcriptional elongation.  The authors further showed that, Chk1 is employed in sensing 
the replication block caused due to stalled replication forks in presence of HU and 
inhibiting Chk1 by caffeine co-treatment relieved the elongation block of p21 gene leading 
to significant accumulation of p21 mRNA and protein. In order to test the requirement of 
p38 MAPK in this elongation pathway, levels of phosphorylated p38 were analyzed under 
conditions where elongation block was relieved (i.e. under caffeine and HU co-treatment 
conditions). Indeed p38 was phosphorylated and hence activated under these conditions 
when p21 was induced, whereas total p38 levels remained unchanged (Fig. 19A). As 
reported previously (Gottifredi et al. 2001; Beckerman et al. 2009) HU treatment induced 
p53 and co-treatment with caffeine and HU induced p21, without affecting p53 protein 
levels induced by HU alone (Fig. 19A). To further confirm the requirement of p38 in this 
pathway, the p38 MAPK specific inhibitor BIRB796 was used to inhibit p38. Inhibition of 
p38 partially blocked the p21 induction upon caffeine and HU co-treatment, without 
affecting the p53 protein levels (Fig. 19B). Interestingly, the enrichment of elongating form 
of RNA polymerase II in the distal regions of the p21 gene observed upon caffeine and 
HU co-treatment conditions was also partially blocked by p38 co-inhibition by BIRB796 
(Fig. 19C). Taken together these findings strongly support the importance of p38 signaling 
in mediating transcriptional elongation p21 gene under stress conditions. 
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Figure 19: Transcriptional elongation of p21 in response to replication stress is 
dependent on p38 MAPK. 
(A) U2OS cells were untreated (unt.) or pretreated with 4 mM caffeine for 1 h and then left 
untreated or were treated with 1.7 mM HU for 24 h. The levels of respective proteins were 
determined by immunoblotting. α-tubulin served as loading control. (B) U2OS cells were 
pretreated with DMSO, 4 mM caffeine, 1 µM BIRB796 or a combination of 4 mM caffeine and 1 
µM BIRB796 and then left untreated or were treated with 1.7 mM HU for 24 h.  p53 and p21 
protein levels were determined by immunoblotting. β-actin served as loading control. (C) U2OS 
cells were treated as in (B). Chromatin was isolated and precipitated with antibody specific for 
phospho-ser2 RNA Pol II. ChIP enriched DNA was amplified by RT-qPCR using the indicated 
amplicons. GAPDH2 promoter was analyzed as a control. !!
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3.10 Inhibition of Aurora B activates both α and β isoforms of p38 MAPK 
without affecting their subcellular localization 
Phosphorylation of p38 triggers a conformational change leading to its translocation into 
the nucleus (Wood et al. 2009). Subcellular localization is an important mechanism by 
which substrate specificity of p38 MAPK is regulated (Roux and Blenis 2004; Raman et al. 
2007). Hence, I was prompted to study the subcellular localization of p38 after Aurora B 
inhibition. Since SB202190 inhibits all the four isoforms of p38 (p38α, p38β, p38γ and 
p38δ), whereas BIRB796 specifically inhibits only the α and β isoforms, the findings so far 
suggest the preferential activation of p38α and/or p38β (as compared to p38γ and p38δ) 
due to Aurora B kinase inhibition. So, future experiments designed to explore the 
mechanism by which p38 was mediating the activation of p21, were concentrated mainly 
on p38α and p38β isoforms.  
To study subcellular localization of p38α and p38β, U2OS-EcoR cells stably expressing 
haemagglutinin (HA) tagged versions of p38α and p38β (HA-p38α and HA-p38β) were 
generated. The expression of HA-p38α and HA-p38β was verified by immunoblotting (Fig. 
20A). Further, these cells showed stabilization of p53 and induction of p21 upon Aurora B 
inhibition by ZM4447439 treatment, indicating that overexpression of these constructs did 
not had any off target effects and did not alter the outcome of Aurora B inhibition. Aurora 
B was inhibited by ZM447439 treatment and the lysates were immunoprecipitated with a 
HA-tag specific antibody and then immunoblotted with an antibody against 
phosphorylated p38. Both α and β isoforms of p38 were phosphorylated upon Aurora B 
inhibition (Fig. 20A). To test whether inhibition of Aurora B or co-inhibition of Aurora B and 
p38 affects the subcellular localization of these isoforms of p38, cells expressing either 
HA-p38α or HA-p38β were treated with ZM447439 alone, SB202190 alone or pretreated 
with SB202190 for 2 h and then treated with ZM447439 for 24 h, fixed and analyzed by 
immunostaining using HA-tag specific antibody. Both HA-p38α and HA-p38β were 
localized in cytoplasm as well in nucleus under control conditions (DMSO panel in Fig. 
20B and C) in accordance with published data (Raingeaud et al. 1995). The subcellular 
localizations of both the isoforms remained unchanged on ZM447439 treatment or 
ZM447439 and SB202190 co-treatment (Fig. 20B and C). From these data it is clear that 
the subcellular localization of p38α and p38β is not influenced by Aurora B inhibition.  
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Figure 20: Inhibition of Aurora B activates both α and β isoforms of p38 MAPK without 
affecting their subcellular localization. 
(A) U2OS-EcoR cells stably expressing either HA-p38α or HA-p38β were treated with 1 µM 
ZM447439 for 24 h and lysates were immunoprecipitated with HA-tag specific antibody. 
Immunoprecipitated proteins were analyzed by blotting with antibodies against HA and 
phosphorylated p38 (p-p38). The input sample was analyzed for with antibodies against HA, p-
p38, p38, p53 and p21. β-actin served as loading control. (B) and (C) U2OS-EcoR cells stably 
expressing either HA-p38α or HA-p38β were treated with DMSO, 1 µM ZM447439, 10 µM 
SB202190 or first pretreated with 10 µM SB202190 for 2 h and then treated with 1 µM 
ZM447439 for 24 h. HA-tagged proteins (in green) and p21 (in red) were detected by 
immunostaining. Nuclei (in blue) were stained with Hoechst 33528.!
 
3.11 Neither p38α nor p38β bind to the p21 gene upon Aurora B inhibition 
It is known that the yeast p38-related MAP kinase, Hog1 associates with the transcribed 
region of osmoresponsive genes and promotes their transcriptional elongation in 
response to osmotic stress (Proft et al. 2006). To investigate, if this is true for human p38 
MAPK as well, the binding of HA-p38α and HA-p38β to the p21 gene locus was studied by 
ChIP. U2OS-EcoR cells stably expressing either HA-p38α or HA-p38β were treated with  
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Figure 21: Neither p38α nor p38β bind to the p21 gene upon Aurora B inhibition. 
(A) U2OS-EcoR cells stably expressing empty vector (EV), HA-p53 or HA-p38α were treated 
with DMSO or 1 µM ZM447439 for 24 h and lysates were subjected to analysis for respective 
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proteins indicated. (B) U2OS-EcoR cells stably expressing HA-p38α, empty vector (C) or HA-p53 
(D) were treated with DMSO or 1 µM ZM447439 for 24 h and chromatin was immunoprecipitated 
with a HA-tag specific antibody. ChIP enriched DNA was amplified by qPCR using the indicated 
amplicons. The GAPDH2 promoter was analyzed as a control. (E) U2OS-EcoR cells stably 
expressing empty vector (EV), HA-p53 or HA-p38 β were treated with DMSO or 1 µM ZM447439 
for 24 h and lysates were subjected to analysis for respective proteins indicated. (F) U2OS-EcoR 
cells stably expressing HA-p38β, empty vector (G) or HA-p53 (H) were treated with DMSO or 1 
µM ZM447439 for 24 h and chromatin was immunoprecipitaed by HA-tag specific antibody. ChIP 
enriched DNA was amplified by qPCR using the indicated amplicons. GAPDH2 promoter was 
analyzed as a control. 
 
ZM447439 and chromatin was isolated and immunoprecipitated with an antibody against 
the HA-tag. U2OS-EcoR cells stably expressing empty vector were used as negative 
control, whereas for positive control U2OS-EcoR cells stably expressing HA-p53 were 
used. Expression of HA-p38α and HA-p38β and induction of p53 and p21 upon Aurora B 
inhibition was verified by immunoblotting (Fig. 21A and E). In ChIP analysis, HA-p38α did 
not show any significant binding to the complete p21 gene locus (similar to empty vector 
expressing cells) either in untreated conditions or upon ZM447439 treatment (Fig. 21B 
and C). Similarly HA-p38β showed the same background binding to the p21 gene locus as 
empty vector (Fig. 21F and G). On the other hand HA-p53 binding was strongly induced at 
the p53 binding site 1 (p53BS1) in the p21 promoter upon Aurora B inhibition by 
ZM447439 treatment as expected (Fig. 21D and H). These results suggest that p38α and 
p38β are not recruited to p21 gene locus after Aurora B inhibition. !
3.12 Elongin A binding to the p21 gene locus is induced upon Aurora B 
inhibition 
Elongin A has been reported to bind p21 gene and mediate its transcriptional elongation 
in response to various cellular stresses (Kawauchi et al. 2013). To investigate the 
involvement of Elongin A in p21 transcriptional elongation, U2OS-EcoR cells stably 
expressing HA-tagged mouse Elongin A (HA-mEloA) were generated. The expression of 
HA-mEloA was verified by immunobloting (Fig. 22A). Further, treatment of these cells with 
ZM447439 resulted in p21 induction and this induction was blocked by p38 inhibition by 
SB202190 co-treatment, indicating that over expression of mouse Elongin A does not 
interfere with the activation of p21 upon Aurora B inhibition (Fig. 22A). U2OS-EcoR cells 
stably expressing HA-mEloA were treated with DMSO, ZM447439 or pretreated with 
SB202190 and then treated with ZM447439. Chromatin was isolated and 
immunoprecipitated with antibody against HA-tag. The binding of HA-mElongin A was 
induced at the core promoter as well as in the coding region the p21 gene towards the 
distal regions on Aurora B inhibition by ZM447439 treatment (Fig. 22B). Interestingly this 
!!
!
Results 
!
! !
65!
enrichment was blocked when p38 was inhibited by SB202190 co-treatment. This 
suggests that Elongin A recruitment to p21 gene locus might be dependent on signaling 
from p38. To confirm this possibility the effect of knockdown of Elongin A on p21 induction 
upon Aurora B inhibition needs to be investigated. 
 
!
 
Figure 22: Binding of Elongin A to the p21 gene locus is induced upon Aurora B 
inhibition. 
(A) U2OS-EcoR cells stably expressing empty vector (EV) or HA-mEloA were treated with 
DMSO, 1 µM ZM447439 alone, 10 µM SB202190 alone or pretreated with 10 µM SB202190 for 
2 h and then treated with 1 µM ZM447439 for 24 h. Levels of HA-mEloA and p21 were 
determined by immunoblotting. β-actin served as loading control. (B) U2OS-EcoR cells stably 
expressing HA-mEloA, were treated as in (A) and chromatin was immunoprecipitated by HA-tag 
specific antibody. ChIP enriched DNA was amplified by qPCR using the indicated amplicons. 
GAPDH2 promoter was analyzed as a control. !!!
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3.13 Aurora B inhibition in interphase is not sufficient for induction of p21 
Recently it has been proposed that Aurora B has a function outside mitosis, during the 
interphase where it mediates degradation of p53 by phosphorylation (Gully et al. 2012). In 
order to test whether the interphase function or the mitotic function of Aurora B is 
necessary for p21 induction, cells were arrested at the G1/S border by thymidine. The 
G1/S arrest was confirmed by flow cytometry (Fig. 23B). Inhibition of Aurora B in 
interphase (in G1/S arrested cells) by ZM447439 treatment did not induce p21 (Fig. 23A, 
lane 3), whereas p21 was strongly induced (Fig. 23A, lane 5) when the cells were first 
released from G1/S block and then treated with ZM447439 (inhibition of Aurora B outside 
interphase). As control, asynchronous cells were treated with ZM447439, which showed 
p21 induction (Fig. 23A, lane 6). Although G1/S arrested cells already showed p53 
stabilization, this stabilization increased when cells were released from G1/S block and 
then treated with ZM443439. Taken together these findings support the conclusion that 
the induction of p53 and p21 is not due to inhibition of interphase function of Aurora B, but 
due to inhibition of its function during mitosis. 
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Figure 23: Aurora B inhibition in interphase is not sufficient for induction of p21. 
(A) U2OS cells were synchronized in G1/S by treatment with 2.5 mM thymidine for 24 h (lanes 2-
5). Thymidine-blocked cells were treated with DMSO or with 1 µM ZM447439 for 24 h either 
without release (lane 2 and 3) or after a 2 h release from the thymidine block (lane 4 and 5). 
Asynchronous cells (lane 1) and asynchronous cells treated with 1 µM ZM447439 for 24 h (lane 
6) served as controls. Levels of p21 were determined by immunoblotting. β-actin served as a 
loading control.  (B) Cell cycle synchronization of the experiment shown in (A) was confirmed by 
flow cytometry. 
This figure was published in similar form in Kumari et al. 2014. !
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3.14 Partial inhibition of Aurora B is sufficient to induce p21 without any 
cytokinesis defects 
Given the various important functions of Aurora B during mitosis and cytokinesis like 
proper chromosome orientation and equal segregation of chromosomes leading to 
generation of euploid cell progeny (Ruchaud et al. 2007; Vader and Lens 2008; Carmena 
et al. 2012) and the proposed involvement of a ‘tetraploidy checkpoint’ in activation of p53 
after cytokinesis failure (Andreassen et al. 2001; Margolis et al. 2003), it was of 
considerable interest to study if binucleation and hence failure of cytokinesis is necessary 
for activation of p53 and p21 after Aurora B inhibition. For this, U2OS and HCT116 cells 
were treated with different doses of Aurora B inhibitors and p21 induction as well as 
cellular defects was studied. 
 
3.14.1 Partial inhibition of Aurora B by low doses of ZM447439 treatment in 
HCT116 cells results in p21 induction without binucleation 
HCT116 cells were treated with increasing concentrations (0.1 µM-1 µM) of ZM447439 for 
24 h and the phosphorylation status of histone H3 (pH3) was monitored by 
immunoblotting, which served as readout for extent of Aurora B inhibition (Fig. 24A) 
(Crosio et al. 2002). At low doses of ZM447439 (0.3 µM and 0.4 µM), Aurora B was 
partially inhibited as compared to the high dose (1 µM). Immunobloting and 
immunofluorescence revealed that p53 and p21 were induced at these low doses (Fig. 
24B and C). Interestingly at these low doses of ZM447439, there were no cytokinesis 
defects as indicated by the presence of mononuclear cells (with p21 induction) and 
absence of multinucleated cells (Fig. 24C). In contrast, at the high dose of 1 µM 
ZM447439, all the cells became multinucleated and enlarged due to repeated failed 
cytokinesis (Fig. 24C). The absence of polyploid cells at low doses of ZM447439 as 
compared to high dose was also confirmed by flow cytometry (Fig. 24D). These findings 
suggest that subtle mitotic defects are sufficient to activate p53 and p21 in response to 
Aurora B inhibition and a complete failure of cytokinesis is not required. 
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Figure 24: Partial inhibition of Aurora B by low doses of ZM447439 treatment in HCT116 
cells results in p21 induction without binucleation. 
(A) HCT116 cells were treated with various concentrations of ZM447439 for 24 h. Histone H3 
phosphorylated at serine 10 (pH3) was analyzed by immunoblotting. β-actin served as a loading 
control. (B) HCT116 cells were treated with 0.3 µM, 0.4 µM or 1 µM ZM447439 for 24 h. Levels 
of p53 and p21 proteins were determined by immunoblotting. α-tubulin served as loading control. 
(C) HCT116 cells were treated as in (B) and level of p21 was determined by immunostaining. 
DNA was counterstained with Hoechst 33258. (D) HCT116 cells were treated as in (B) and 
FACS was done to determine the fraction of cells in different phases of the cell cycle. 
Parts of this figure were published in similar form in Kumari et al. 2014. !
 
3.14.2 Partial inhibition of Aurora B by low doses of ZM447439 treatment in 
U2OS cells results in p21 induction without binucleation 
To confirm that the effects seen at low doses of ZM447439 are not specific for HCT116 
cells, another cell line U2OS was also treated with different doses (0.5 µM and 1 µM) of 
ZM447439. Treatment of U2OS cells with 0.5 µM ZM447439 did not lead to cytokinesis 
defects, but induced p21 at comparable levels to the higher dose of 1 µM (Fig. 25A). Also, 
p53 and p-p38 were activated at these low doses of Aurora B inhibitor (Fig. 25B), 
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indicating that the p38-p53-p21 pathway activation in response to Aurora B inhibition is 
sensitive to defects in mitosis and not to inhibition of cytokinesis. The cell cycle profiles of 
U2OS cells treated with 0.5 µM and 1 µM ZM447439, further confirmed that there was no 
cell division failure at the low doses (Fig. 25C). !
!
 
Figure 25: Partial inhibition of Aurora B by low doses of ZM447439 treatment in U2OS 
cells results in p21 induction without binucleation. 
(A) U2OS cells were treated with DMSO, 0.5 µM or 1 µM ZM447439 for 24 h. p21 (in red) and α-
tubulin (in green) was detected by immunostaining. Nuclei (in blue) were stained with Hoechst 
33528. (B) U2OS cells were treated as in (A) and respective protein levels were determined by 
immunoblotting. (C) U2OS cells were treated as in (A) and analyzed by FACS to determine cells 
in different phases of cell cycle. 
Parts of this figure were published in similar form in Kumari et al. 2014. !!
3.14.3 Partial inhibition of Aurora B by low doses of AZD1152-HQPA 
treatment in U2OS cells results in p21 induction without binucleation 
To exclude the possibility that the phenotypes observed in U2OS and HCT116 cells by 
low doses of ZM447439 treatment are artifact, another inhibitor of Aurora B, AZD1152-
HQPA was used. U2OS cells were treated with 50 nM and 100 nM AZD1152-HQPA. 
Although both concentrations of AZD1152-HQPA induced comparable levels of p53, p-
p38 and p21 (Fig. 26A), there were no binucleated or multinucleated cells at the lower 
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dose of 50 nM as compared to higher dose of 100 nM AZD1152-HQPA. Taken together, 
all these data with low doses of two different Aurora B inhibitors in two different cell lines 
indicate that tetraploidy and hence cytokinesis failure is not required for p38-p53-p21 
activation in response to Aurora B inhibition.  !
!
 
Figure 26: Partial inhibition of Aurora B by low doses of AZD1152-HQPA treatment in 
U2OS cells results in p21 induction without binucleation. 
(A) U2OS cells were treated with DMSO, 50 nM or 100 nM AZD1152-HQPA for 24 h. Respective 
protein levels were determined by immunoblotting. (B) U2OS cells were treated as in (A) and 
p21 levels (in red) were determined by immunostaining. Nuclei (in blue) were stained with 
Hoechst 33528. 
This figure was published in similar form in Kumari et al. 2014. !!
3.15 Partial Aurora B inhibition results in increased aneuploidy 
The activation of p38-p53-p21 pathway in absence of any cytokinesis defects upon partial 
Aurora B inhibition suggests that chromosomal segregation errors due to Aurora B 
inhibition might be responsible for activation of this pathway. To answer this possibility the 
frequency of aneuploidy was determined by carrying out interphase FISH assays using 
fluorescent probes specific for chromosome 7 and 8. Partial inhibition of Aurora B by low 
doses of (0.3 µM or 0.4 µM) ZM447439 treatment (for 48 h) in HCT116 cells indeed 
caused increased aneuploidy as indicated by an increase in the deviation from mode for 
chromosome 7 from 5.01 % to 6.47 % (with 0.3 µM ZM447439) and to 11.84 % (with 0.4 
µM ZM447439) and for chromosome 8 an increase from 3.34 % to 6.47 % (with 0.3 µM 
ZM447439) and to 14.11 % (with 0.4 µM ZM447439) (Fig. 27A and B). Hence p53 and 
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p21 activation on partial Aurora B inhibition correlates with increased chromosome 
segregation errors in absence of tetraploidy. !
!
 
Figure 27: Partial Aurora B inhibition results in increased aneuploidy. 
(A) Example microphotographs of interphase FISH assays of HCT116 cells treated with DMSO, 
0.3 µM or 0.4 µM ZM447439 for 48 h. Chromosome 7: red; chromosome 8: green (B) 
Quantification of interphase FISH signals for chromosomes 7 and 8 in DMSO and ZM447349 
treated HCT116 cells shown in (A). The difference in the percentage of cell off the mode after 
treatment with 400 nM ZM447439 was statistically significant (chromosome 7 or 8 p-values 
<0.001). With 300 nM ZM447439 the difference in percentage of cells of the mode was not 
significant for chromosome 7 but was significant for chromosome 8 (p=0.009). Chi-squared test 
was used to analyze the data. 
This figure was published in similar form in Kumari et al. 2014. !!
3.16 p21 induction after partial Aurora B inhibition does not involves DNA 
damage 
A plausible cause of p21 activation due to partial Aurora B inhibition might be 
chromosomal segregation errors causing DNA damage, which has been reported to 
activate p53 (Thompson and Compton 2010b; Janssen et al. 2011).  Presence of DNA 
damage can be detected by classical markers like presence of phosphorylated H2A.X (a 
widely used marker for DNA damage response as a result of double strand breaks) or 
presence of activated ATM (ataxia-telangiectasia mutated) and ATR (ATM and Rad3-
related) kinases (Zhou and Elledge 2000; Falck et al. 2005). All these possibilities were  
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Figure 28: p21 induction after partial Aurora B inhibition does not involve DNA damage. 
(A) U2OS cells were treated with DMSO, 0.5 µM ZM447439, 1 µM ZM447439 for 24 h or with 1 
µM doxorubicin (Dox.) for 6 h. p21, p-H2A.X and β-actin protein levels were determined by 
immunoblotting. (B) U2OS cells were treated as in (A) and protein levels of phosphorylated 
ATM/ATR substrates and p21 were detected by immunoblotting. β-actin served as a control. (C) 
U2OS cells were pretreated with the indicated concentration of VE821 for 2 h and then treated 
with 1 µM ZM447439 for 24 h. p21 levels were determined by immunoblotting.  β-actin served as 
a control. (D) U2OS cells were pretreated with the indicated concentration of KU5593 for 2 h and 
then treated with 1 µM ZM447439 for 24 h. p21 levels were determined by immunoblotting.  β-
actin served as a control. (E) U2OS cells were pretreated with DMSO, 1 µM VE821, 10 µM 
KU5593 or a combination of 1 µM VE821 and 10 µM KU5593 for 2 h and then treated with 1 µM 
doxorubicin or left untreated for 6 h. p-Chk1(Ser345), p-Chk2(Thr68) and p-ATM/p-ATR 
substrate protein levels were determined by immunoblotting. β-actin served as a control.  
This figure was published in similar form in Kumari et al. 2014. !
explored. However there was no evidence of DNA damage upon partial Aurora B 
inhibition as evident by absence of p-H2A.X in U2OS cells upon ZM443439 treatment, 
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whereas p-H2A.X was detected by treatment with the DNA damaging agent, doxorubicin 
(used as positive control) (Fig. 28A). Also, phosphorylation of ATM/ATR kinase substrates 
was not detected in response to ZM447439 treatment (at both low and high doses) (Fig. 
28B) while a positive result was obtained with doxorubicin, which induced the 
phosphorylation of ATM/ATR substrates (Fig. 28B). To further confirm that ATM and ATR 
kinases are not involved in p21 induction in response to Aurora B inhibition, the effects of 
ATM inhibitor KU5593 (Hickson et al. 2004) and ATR inhibitor VE821 (Reaper et al. 2011) 
on p21 induction mediated by ZM447439 treatment was investigated. However, none of 
these inhibitors were able to prevent the p21 induction upon ZM447439 treatment, 
indicating that they are not involved in the activation of the p53-p21 pathway after Aurora 
B inhibition (Fig. 28B and C). In order to test if the inhibitors were working, the effect of 
ATM inhibitor KU5593 on p-Chk2(Thr68) and of ATR inhibitor VE821 on p-Chk1(Ser345) 
induction upon doxorubicin treatment was studied. As expected, the phosphorylation of 
Chk1 at Ser-345 was efficiently blocked by VE821 and the phosphorylation of Chk2 at 
Thr-68 was efficiently blocked by KU5593, while the combined inhibitor treatment 
efficiently blocked the phosphorylation of ATM/ATR substrates (Fig. 28E). Overall, these 
results indicate that the DNA damage does not contributes to p21 activation after 
impairment of Aurora B function. !
3.17 Partial inhibition of Aurora B results in proteotoxic stress but no 
autophagy 
Aneuploidy has been linked with increased proteotoxic stress due to protein imbalance, in 
humans as well yeast (Stingele et al. 2012; Oromendia et al. 2012).  Proteotoxic stress 
leads to formation of ubiquitinated protein aggregates, which can be detected by 
immunoblotting. Indeed increased poly-ubiquitin aggregates were detected in both U2OS 
and HCT116 cells upon partial Aurora B inhibition by ZM447439 treatment (Fig. 29A). 
Partial Aurora B inhibition by AZD1152-HQPA treatment in U2OS cells also resulted in 
generation of poly-ubiquitin aggregates (Fig. 29B). Since aneuploidy has also been linked 
to increased autophagy (Stingele et al. 2013), the effect of partial Aurora B inhibition on 
two autophagy markers (p62 and LC3) was investigated. However the protein levels of 
these markers (p62 and LC3) remained unchanged upon partial Aurora B inhibition by low 
dose ZM447439 treatment in both U2OS and HCT116 cells (Fig. 29C). These findings 
demonstrate that aneuploidy caused due to partial Aurora B inhibition generates 
proteotoxic stress. !
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Figure 29: Partial inhibition of Aurora B results in proteotoxic stress but no autophagy. 
(A) U2OS and HCT116 cells were treated with 0.5 µM (for 24 h) or 0.3 µM (for 48 h) ZM447439, 
respectively. As a control, cells were treated with DMSO. Ubiquitin conjugates were detected by 
immunoblotting. β-actin served as a control. (B) U2OS cells were treated with DMSO, 50 nM or 
100 nM AZD1152-HQPA for 24 h. Ubiquitin conjugates were detected by immunoblotting. β-actin 
served as a control. (C) U2OS and HCT116 cells were treated as in (A) and protein levels of p62 
and LC3 were determined by immunoblotting. β-actin served as a control. !!
3.18 Partial inhibition of Aurora B correlates with increased generation of 
reactive oxygen species (ROS) 
The metabolic imbalance resulting due to aneuploidy results in generation of reactive 
oxygen species (ROS) (Li et al. 2010). Hence it was speculated that ROS might be 
generated due to aneuploidy after partial Aurora B inhibition. To test the production of 
ROS, the dye H2DCF-DA was used, which is a general oxidative stress indicator and 
gives green fluorescence in presence of ROS. Interestingly partial Aurora B inhibition by 
ZM447439 treatment resulted in generation of significant amount of ROS (Fig. 30A). 
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Figure 30: Partial inhibition of Aurora B correlates with increased generation of reactive 
oxygen species (ROS). 
(A) Detection of ROS with the fluorescent dye H2DFC-DA in U2OS cells treated with DMSO or 
0.5 µM ZM447439 for 24 h. (B) ROS generation was analyzed with MitoSox Red in U2OS cells 
treated with DMSO, 0.5 µM ZM447439 or co-treated with 0.5 µM ZM447439 and 5 mM Tiron for 
24 h. Bar 10 µm. (C) U2OS cells were treated as in (B). Levels of p53, p21, phosphorylated p38 
(p-p38) and β-actin were determined by immunoblotting. (D) U2OS cells were treated for 48 h 
with DMSO, 0.5 µM ZM447439, 5 mM Tiron or 0.5 µM ZM447439 and 5 mM Tiron. Cells were 
pulse labeled with 15 µg/ml BrdU for 2 h. The percentage of BrdU-positive cells was determined 
by immunofluorescence. (E) Quantification of the BrdU positive cells shown in (D). Error bars 
represent standard deviation of four independent experiments. The differences between DMSO 
and ZM447439 (p=0.005) and between ZM447439 and ZM447439+Tiron (p=0.0019) were 
statistically significant (student's t-test). (F) U2OS cells were treated as in (B) and p21 mRNA 
levels were determined by qRT-PCR. (G) U2OS cells were treated with DMSO, 0.5 µM 
ZM447439 or co-treated with 0.5 µM ZM447439 and 5 mM Tiron for 72 h. Protein levels of p21 
and the E2F target genes (E2F1, B-Myb, Cyclin A) were determined by immunoblotting. β-actin 
served as loading control. 
Parts of this figure were published in similar form in Kumari et al. 2014. 
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To specifically test the type of ROS generated, MitoSox Red (which detects mitochondrial 
superoxide free radicals) was used. Staining by MitoSox Red gave a strong red 
fluorescence in presence of partial Aurora B inhibition (Fig. 30B), suggesting that 
mitochondrial superoxide anions are generated under conditions of aneuploidy generated 
due to partial Aurora B inhibition. 
The next question was whether superoxide anions are required for activation of the p38-
p53-p21 pathway. To answer this, an antioxidant 4,5-dihydroxybenzene-1,3-disulfonate 
(Tiron, a Vitamin E analog), was used which is a superoxide anion scavenger. Indeed, co-
treatment with Tiron and ZM447439 rescued the induction of p-p38 and p21 observed 
upon ZM447439 treatment alone (Fig. 30C). Tiron co-treatment also partially prevented 
the activation of p53 by ZM447439 (Fig. 30C). Hence these findings implicate that ROS is 
involved upstream of p53 and p38 MAPK in response to partial Aurora B inhibition. 
Further, it was important to know if ROS is also required for the cell cycle arrest observed 
on partial Aurora B inhibition. For this, DNA synthesis was measured by BrdU 
incorporation. Treatment with ZM447439 induced cell cycle arrest and hence resulted in a 
decrease in the percentage of BrdU positive cells. Interestingly, co-treatment with Tiron 
rescued the BrdU incorporation to a level similar to the control treated cells (Fig. 30D and 
E). Collectively these data indicate that partial Aurora B inhibition leads to generation of 
ROS, which in turn is required for cell arrest by mediating p53 and p38 dependent 
activation of p21. 
 
3.19 Drugs that target aneuploid cells synergize with inhibition of Aurora B 
In order to explore the functional and clinical significance of these studies, the ability of 
Aurora B inhibitors to synergize with drugs to which aneuploid cells are sensitive, for 
example the heat shock protein 90 (Hsp90) inhibitor 17-AAG and AICAR an activator of 
the AMP-activated protein kinase (AMPK) (Tang et al. 2011) was analyzed. To do this, 
HCT116 cells were seeded at very low density (700 cells/well in a 6-well plate) and 
treated with DMSO, AICAR alone, 17AAG alone, combination of low dose of ZM447439 
(400 nM) and AICAR or combination of low dose of ZM447439 (400 nM) and 17AAG. The 
number of colonies was determined after 14 days, by fixing the cells and staining with 
crystal violet. Treatment with AICAR alone moderately inhibited proliferation of cells 
whereas with 17AAG alone and low dose of ZM447439 had no effect (Fig. 31A). 
Interestingly the combination of low dose of ZM447439 with either AICAR or 17AAG 
markedly reduced the colony formation (Fig. 31A). This effect of the combination of 
ZM447439 with these drugs was further confirmed in U2OS cells (Fig. 31C) and validated 
by quantification of the dye extracted from these assays (Fig. 31B). 
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Figure 31: Drugs that target aneuploid cells synergize with inhibition of Aurora B. 
(A) HCT116 and U2OS cells were treated with DMSO, AICAR (200 µM), 17-AAG (8nM), 
ZM447439 (0.4 µM for HCT116, 0.5 µM for U2OS), a combination of ZM447439 and AICAR or a 
combination of ZM447439 and 17AAG. 14 days later, colonies were fixed and stained with 
crystal violet. (B) Quantification of the colonies shown in (A). The dye was extracted and 
absorbance was determined at 590 nm. The experiment was performed in triplicates. Error bars 
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represent standard deviation. (*P<0.05, ***P<0.01, student’s t-test). (C) Soft-agar assays were 
performed to analyze anchorage independent growth of HCT116 cells treated with DMSO, 
AICAR (200 µM), ZM447439 (0.4 µM) or a combination of 0.4 µM ZM447439 and 200 µM 
AICAR. 
This figure was published in similar form in Kumari et al. 2014. 
 
Next, the ability of the combination of ZM447439 and AICAR to inhibit oncogenic 
transformation was explored by determining the ability of HCT116 cells to grow 
independently of anchorage in presence of these drugs. Low dose ZM447439 or AICAR 
treatment had no effect on colony formation, whereas the combined treatment strongly 
prevented the ability of HCT116 cells to grow independent of anchorage (Fig. 31C). 
Together these results support the notion that low doses of Aurora B inhibitor ZM447439 
synergize with drugs (AICAR and 17AAG), to which aneuploid cells are sensitive, to inhibit 
cell proliferation and transformation. 
 
3.20 The synergism of Aurora B inhibitor with AICAR/17AAG in decreasing 
cell proliferation is due to a cooperative effect on induction of cell cycle 
inhibitor proteins 
The decrease in proliferation of cells upon co-treatment with ZM447439 and AICAR (and 
17AAG) might be due to an additive effect on activation of cell cycle inhibitor p21 (Chae et 
al. 2012; Vaseva et al. 2011). In order to explore this possibility U2OS cells were treated 
with DMSO, ZM447439 (0.5 µM), AICAR (200 µM), 17AAG (8 nM), a combination of 
ZM447439 and AICAR or a combination of ZM447439 and 17AAG for 12 h or 24 h. 
Interestingly, AICAR cooperated with ZM447439 to induce p21 and p53 at 12 h and also 
to induce p27 after 24 h (Fig. 32A and B). 17AAG also augmented p21 induction after 12 
h co-treatment with ZM447439 (Fig. 32C). These results indicate that AICAR and 17AAG 
act together with ZM447439 at an early time-point to cause growth inhibition by increasing 
the expression of well-known cell cycle inhibitors p53, p21 and p27. 
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Figure 32: AICAR and 17AAG cooperate with ZM447439 to induce p21, p53 and p27. 
(A) U2OS cells were treated with DMSO, 0.5 µM ZM447439, 200 µM AICAR or a combination of 
ZM447439 (0.5 µM) and AICAR (200 µM) for 12 h and protein levels of p53, p21, and β-actin 
were determined by immunoblotting. (B) U2OS cells were treated with DMSO, 0.5 µM 
ZM447439, 200 µM AICAR or a combination of ZM447439 (0.5 µM) and AICAR (200 µM) for 24 
h and protein levels of p21 and p27 were determined by immunoblotting. β-actin served as 
loading control. (C) U2OS cells were treated with DMSO, 0.5 µM ZM447439, 8 nM 17AAG or a 
combination of ZM447439 (0.5 µM) and 17AAG (8 nM) for 12 h and protein levels of p21 and β-
actin were determined by immunoblotting. 
Parts of this figure were published in similar form in Kumari et al. 2014. 
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4 Discussion 
 
It has been reported that the tumor suppressor p53 and its target gene p21 (a cell cycle 
inhibitor) are activated as a consequence of Aurora B inhibition. However the detailed 
molecular requirements for p21 induction have not been established. In this study I 
investigated the pathways leading to p21 activation due to Aurora B inhibition in detail. 
Using chemical inhibitors against Aurora B (ZM447439 and AZD1152-HQPA) and against 
p38 MAPK (SB202190 and BIRB796), I demonstrate here that, induction of p21 in 
response to Aurora B inhibition requires activation of p38 MAPK, while p53 induction is 
independent of p38 MAPK activity. p38 mediates the activation of p21 by stimulating the 
transcriptional elongation of p21 gene by RNA Polymerase II. Further I show that partial 
inhibition of Aurora B by low doses of Aurora B inhibitors is sufficient for activation of p38, 
p53 and p21 in the absence of any cytokinesis defects. Instead, aneuploidy and 
subsequent generation of oxidative stress accomplish the activation of p38-p53-p21 
pathway under partial Aurora B inhibition conditions. Finally I provide evidence that cancer 
cells treated with low doses of Aurora B inhibitor are sensitive to drugs that specifically 
target aneuploid cells such as AICAR and 17AAG.  
 
4.1 p38 MAPK is necessary for p21 induction and is required for 
transcriptional elongation stage of p21 gene regulation in response to 
Aurora B inhibition 
Inhibition of Aurora B activates p38, a stress activated mitogen kinase by inducing 
phosphorylation of p38 (active form of p38 MAPK) without changing the total p38 protein 
levels (Fig. 13A).  Both isoforms of p38, p38α and p38β are phosphorylated upon Aurora 
B inhibition (Fig. 20A). Inhibition of p38 MAPK (by two chemical inhibitors SB202190 and 
BIRB796) prevents the p21 induction mediated by two different Aurora B inhibitors 
(ZM447439 and AZD1152-HQPA) in two different cell lines (Fig. 13B-E). Conversely, p38 
inhibition does not block the p21 activation in response to DNA damage induced by 
doxorubicin (Fig. 13F). These data strongly point towards the specific requirement of p38 
in p21 induction in context of Aurora B inhibition. In fact a number of other studies have 
reported the involvement of p38 MAPK in cell cycle arrest and activation of p53 and p21 
due to mitotic stress such as disruption of centriole function (Mikule et al. 2007; Uetake et 
al. 2007; Thompson and Compton 2010).  
Inhibition of p38 does not influence p53 induction, indicating that it is regulating p21 
without affecting the protein levels of p53 (Fig.13B-E). Also p38 does not modulate the 
stability of the p21 mRNA (as observed by Tanja Ulrich and published in Kumari et al. 
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2013) or protein (Fig. 16B and C). Chromatin immunoprecipitation analysis at the p21 
gene locus revealed that p53 binding is strongly induced at its binding site (p53BS1) in the 
p21 promoter upon Aurora B inhibition but this binding remains unaltered upon p38 co-
inhibition (Fig. 17B and D, Fig. 18C). This indicates that p53 binding to the p21 gene locus 
does not require p38 signaling. The loading of RNA Polymerase II to the promoter of p21 
gene also occurs independently of p38 activity (Fig. 18D). Interestingly, the enrichment of 
the elongating form of RNA Polymerase II in the p21 coding region and formation of full-
length p21 primary transcripts requires p38 signaling (Fig. 18E and F). Collectively, these 
data identify p38 MAPK as a downstream mediator of Aurora B in regulating p21 gene 
expression through its transcriptional elongation. Regulation of p21 gene expression by 
modulation of transcriptional elongation by RNA Polymerase II has been demonstrated by 
several other studies (Gomes et al. 2006; Kawauchi et al. 2013; Valin et al. 2013). 
Regulation at the transcriptional elongation stage occurs at the promoters of stress 
responsive genes, which are characterized by the presence of paused RNA Polymerase II 
at the promoter in the uninduced state. This ensures rapid induction of gene transcription 
once the cell receives a stress signal (Muse et al. 2007; Price 2008; Adelman and Lis 
2012). In fact I also found that the RNA Polymerase II was paused at the p21 gene 
promoter in absence of any stimulation (Fig. 18D). Collectively these findings demonstrate 
a yet unknown role of p38 MAPK in mediating transcriptional elongation of p21 gene and 
hence its importance in fine-tuning the stress signaling activated due to Aurora B 
inhibition.  
 
4.2 p38 is not recruited to p21 gene locus after Aurora B inhibition 
In light of the published findings that the yeast counterpart of human p38, Hog1 binds to 
the coding regions of genes and has a role in transcriptional elongation (Proft et al. 2006), 
it was of interest to study if the mammalian counterpart also has the same function. As the 
commercially available antibodies for p38 and p-p38 do not work in ChIP, I performed HA-
ChIP assays with cells stably expressing HA-p38α and HA-p38β. However, none of the 
p38 isoforms bound to p21 gene locus upon Aurora B inhibition (Fig. 21B and F). 
Nevertheless, the possibility that the endogenous p38 is recruited to the p21 gene locus 
after Aurora B inhibition cannot be excluded. It is possible that p38 is binding to the p21 
gene locus through interaction with the RNA Polymerase II transcription machinery via 
transient interactions, and that these interactions are too weak to be detected by the 
crosslinking conditions used in the ChIP assay. There is evidence that mammalian p38 
MAPK is recruited to the promoter as well as to the coding regions of stress responsive 
genes such as c-Fos, IL8, Cox2 via the respective transcription factors Elk1, NFκB and 
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AP1, in response to osmostress (Ferreiro et al. 2010). Besides the possibility of direct 
binding of p38 to the p21 gene locus, another possibility is that p38 is recruiting (or 
phosphorylating resulting in differential activity) other mediators of the transcriptional 
elongation machinery (transcription factors and other DNA-binding proteins such as 
chromatin modifiers) to the p21 gene locus to activate its elongation. For instance, p38 
has an essential role in muscle differentiation by phosphorylating BAF60c, a subunit of 
SWI/SNF complex, which promotes the recruitment of the chromatin remodeling complex 
SWI/SNF along with the muscle transcription factor MyoD (Simone et al. 2004; Forcales et 
al. 2012). p38 also phosphorylates several transcription factors including myocyte 
enhancer factors 2C and 2A (MEF2C and 2A) (Han et al. 1997; Zhao et al. 1999), p53 
(Bulavin et al. 1999) and C/EBP (c-AMP response element binding protein) family of 
transcription factors (Wang and Ron 1996).  
Regarding transcriptional elongation control by p38, one interesting candidate is Elongin 
A. Kawauchi et al. (2013) recently demonstrated that Elongin A is necessary for 
transcriptional elongation of stress responsive genes including p21 and ATF3 under stress 
conditions. In fact I could also demonstrate that recruitment of Elongin A to the p21 gene 
locus is induced by Aurora B inhibition and also that this recruitment is blocked upon p38 
co-inhibition (Fig. 22B). Requirement of Elongin A for p21 induction requires further 
validation by studying the effect of Elongin A knockdown (by siRNA/shRNA) on p21 
activation after Aurora B inhibition. Another relevant mediator in transcriptional elongation 
of p21 after Aurora B inhibition is CDK8, a component of the Mediator complex. Recently 
it was shown that under hypoxia conditions, HIF1A recruits CDK8 to stimulate 
transcriptional elongation by RNA Polymerase II (Galbraith et al. 2013). It will be 
interesting to study if CDK8 is also recruited to p21 gene locus upon impairment of Aurora 
B function, and if yes, then whether its recruitment is p38 dependent. Exploring the 
mechanism by which p38 is mediating transcriptional elongation of p21 gene upon 
disruption of Aurora B function will be of foremost importance in future experiments. 
 
4.3 Disruption of mitotic function of Aurora B is necessary for p21 induction, 
but tetraploidy is not required 
Chemical inhibition of Aurora B by ZM447439 and AZD1152-HQPA generates polyploidy 
and induces p21 at both mRNA and protein levels (Fig. 10, Fig. 11 and Fig. 16A). 
Knockdown of Aurora B also induces p21 (Fig. 10D). This induction of p21 is p53 
dependent as absence of p53 or disruption of its function (by SV40 large T antigen) failed 
to induce p21 upon Aurora B inhibition (Fig. 12B and C). These findings are in line with a 
number of reported studies (Gizatullin et al. 2006; Tao et al. 2008; Kaestner et al. 2009). 
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p53 is stabilized due to prevention of its degradation by Aurora B when Aurora B is 
inhibited as reported by Gully et al. (2012). p53 is a tumor suppressor and guardian of 
genome, which prevents cell cycle progression under stress conditions by regulating the 
induction of cell cycle inhibitor protein p21. After defects in mitosis, p53 causes a pseudo-
G1 arrest (cells arrested in G2/M phase with 4N DNA content) (Lanni and Jacks 1998). 
This is evident by the accumulation of cells with 4N DNA content (Fig. 10B and 11B), p21 
induction (Fig. 10C) and presence of dephosphorylated pRb upon ZM447439 treatment 
(Fig. 15B). This ensures that the cells with abnormal DNA content and altered ploidy 
status are eliminated by apoptosis after prolonged cell cycle arrest or undergo 
senescence. An interesting question to be answered is that, when during the cell cycle, is 
p53 activated after Aurora B inhibition. For example, in mitosis, as proposed by 
(Blagosklonny 2006) or in the subsequent G1 phase. In support of the second possibility, 
a recently published study reported that, Aurora B also plays a role during interphase in 
mediating p53 degradation by phosphorylating it, in addition to it’s functions during mitosis 
(Gully et al. 2012). Hence, it might be possible that p53 stabilization resulting from Aurora 
B inhibition during interphase is responsible for p21 induction. Alternatively, it is also 
possible that p21 induction is due to signaling pathways activated due to failed mitosis. In 
order to tease apart these alternate hypotheses, Aurora B was inhibited in interphase or 
during mitosis. When cells are treated with ZM447439 during interphase, p21 is not 
induced, whereas a strong p21 induction occurs when cells progress through mitosis after 
treatment with ZM447439 (Fig. 23). Hence, in order for p21 to be induced, inhibition of 
Aurora B during mitosis is necessary. The requirement of mitotic entry for Aurora B 
inhibition mediated p53 induction has been shown by a previous study which 
demonstrated that inhibition of mitotic entry by CDK1 inhibitor prevented the p53 induction 
by Aurora B inhibitor (Dreier et al. 2009). Hence, these findings imply that defects during 
mitosis are responsible for activation of p53-p21 pathway. This result is not in agreement 
with the recently published findings, where it was shown that knocking out Aurora B  
(using conditional MEFs) during quiescence (G0) phase induces p21 (Trakala et al. 2013). 
The observed disparity between my study and by Trakala et al. might be due to the 
different cell systems used (human cells vs. primary mouse cells respectively) and hence 
point towards different requirements for p21 induction after Aurora B inhibition in these 
two systems, which certainly requires further investigation. 
Treatment of U2OS and HCT116 cells with doses of Aurora B inhibitors, which are half (or 
below) of the dose at which severe cytokinesis defects are observed, still induces p53, 
p38 and p21 (Fig. 24B and C, Fig. 25A and B, Fig. 26A). Interestingly, under conditions of 
partial Aurora B inhibition there is no cytokinesis failure as indicated by the presence of 
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mononuclear cells with low doses of Aurora B inhibitors as compared to a large number of 
multinucleated cells observed with higher doses (Fig. 24C, Fig. 25A, Fig. 26B). Also the 
cell cycle profiles of cells with partial Aurora B inhibition resemble with that of control cells, 
showing no obvious changes in their profile as compared to cells with complete Aurora B 
inhibition, which have a highly distorted profile with a large polyploid fraction (Fig. 24D and 
Fig. 25C). The protein levels of phosphorylated histone H3 (pH3, a Aurora B substrate) 
decreased with increasing concentrations of ZM447439, indicating the extent of Aurora B 
inhibition (Fig. 24A). Since the effect of partial Aurora B inhibition on cell division, cell 
cycle profile and the p38-p53-p21 pathway was confirmed using two chemical inhibitors 
against Aurora B and in two cell lines, the possibility that these effects were artifact is 
highly unlikely. This finding implies that complete inhibition of cytokinesis and subsequent 
generation of a tetraploid state is not necessary for induction of the p38-p53-p21 pathway, 
hence supporting the notion that the cell cycle arrest does not requires a ‘tetraploidy 
checkpoint’. It has been proposed that the tetraploidy resulting due to cytokinesis failure 
activates a ‘tetraploidy checkpoint’ which counts the number of chromosomes and 
centrosomes resulting in cell-cycle arrest in subsequent G1 phase by activation of p53 
and p21 (Andreassen et al. 2001; Margolis et al. 2003). In addition to the evidence 
presented here, other studies (Uetake 2004; Wong and Stearns 2005) also support that a 
tetraploidy checkpoint does not exists. 
 
4.4 Partial Aurora B inhibition generates aneuploidy and subsequently 
proteotoxic stress and oxidative stress 
When Aurora B is inhibited partially, although no tetraploidy was observed, an increase in 
chromosome misseggregation (as quantified by FISH assay) and hence aneuploidy is 
observed (Fig. 27). This could be due to inhibition of the ability of Aurora B to resolve 
merotelic attachments (where one kinetochore is attached to microtubules emanating from 
opposite spindle poles). Indeed it has been reported previously that at low doses of 
Aurora B inhibitor ZM447439, the frequency of merotelic attachments increased from 8 to 
50% in Ptk1 cells (Cimini et al. 2006). Cimini et al. (2006) proposed that this is due to 
increased stabilization of microtubule-kinetochore interactions upon partial Aurora B 
inhibition resulting in anaphase lagging chromosomes. The same study by Cimini et al. 
shows that at low doses of ZM447439, there is only a partial inhibition of histone H3 
phosphorylation, consistent with my findings (Fig. 24A). Induction of p53 and p21 due to 
aneuploidy is also consistent with the findings of Thompson and Compton (2010), where 
they show that chromosomal missegregations caused either by monastrol washout or by 
siRNA mediated knockdown of the mitotic kinesin MCAK (mitotic centromere-associated 
!!
!
Discussion 
!
! !
86!
kinesin) induces p53 and p21. Aneuploidy generated by other means such as due to 
compromised SAC components also induces p21 (Li et al. 2010). 
The findings of the present study suggest that when Aurora B activity is partially blocked, 
its functions in regulating kinetochore-microtubule turnover (required for faithful 
chromosome segregation) are preferentially affected, while its functions at the midbody 
(required for proper execution of cytokinesis) remain unperturbed resulting in only 
chromosome segregation defects (causing aneuploidy) in absence of any cytokinesis 
defects. This may be due to abundance of PP1 and PP2A phosphatases near the 
centromeres at the kinetochores as compared to other regions in the cell such as 
chromosome arms and midbody, due to preferential targeting of these phosphatases to 
the centromere (Kitajima et al. 2006; Posch et al. 2010). In future experiments it will be 
interesting to study the inhibition of kinetochore substrates (Hec1, MCAK) vs. midbody 
substrates (MgcRacGAP, MKLP1) of Aurora B under conditions of partial and complete 
Aurora B inhibition.  
In a state of aneuploidy, the chromosome complement is not an exact multiple of the 
haploid karyotype, as a result of which there is a disturbance in the stoichiometric ratio of 
the proteins due to absence/presence of extra chromosomes in the cell. This in turn 
causes burden on the mechanisms for protein quality control (chaperone system) and 
protein clearance/degradation (proteasome, autophagy), causing proteotoxic stress (Fig. 
33).  
 
!
Figure 33: Proteotoxic stress in response to aneuploidy.  
Figure taken from (Gordon et al. 2012). 
 
Indeed ubiquitin aggregates are accumulated in the cell as a result of proteotoxic stress 
caused by partial Aurora B inhibition (Fig. 29A and B). A similar correlation between 
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aneuploidy and proteotoxic stress has been demonstrated in yeast (Oromendia et al. 
2012) as well human cell lines (Stingele et al. 2012). Although proteotoxic stress causes 
activation of autophagy (Stingele et al. 2013), there was no evidence of autophagy under 
conditions of partial Aurora B inhibition (Fig. 29C). However involvement of proteasomal 
pathway for degradation of the accumulated ubiquitinated protein aggregates remains to 
be explored. This could be addressed by using proteasomal inhibitors. 
Partial Aurora B inhibition also causes generation of oxidative stress as indicated by 
production of reactive oxygen species (ROS). Additionally ROS is required induction of p-
p38 and p21 as well as for cell-cycle arrest under partial Aurora B conditions (Fig. 30). 
Specifically superoxide anions (O2•−) are generated by partial Aurora B function 
impairment as indicated by positive MitoSox Red staining upon low dose ZM447439 
treatment (Fig. 30B). Scavanging of superoxide anions by antioxidant Tiron, prevents the 
activation of p-p38 and p21, as well rescues the cell cycle arrest and expression of E2F 
target genes caused by partial Aurora B inhibition (Fig. 30C-G). These data demonstrate 
that ROS is required for activation of the p38-p53-p21 signaling and for mounting 
subsequent cell cycle arrest after Aurora B inhibition. ROS might be generated due to the 
disturbed metabolic profile of the cell caused by the protein imbalance as a result of an 
altered chromosome complement (Li et al. 2010; Fang and Zhang 2011). Aneuploidy has 
been shown to activate p53 through ATM and ROS (Li et al. 2010). In summary, 
aneuploidy and resulting proteotoxic stress caused by Aurora B inhibition generates ROS 
which acts upstream of p38 to activate p21 and this in turn cause cell cycle arrest. One 
mechanism by which ROS could activate p38 is by activating the upstream kinase of p38, 
ASK1 by causing its dissociation from glutathione-S-transferase Mu and Thoiredoxin (Trx) 
(Fig. 34) (Dorion 2002; Liu 2002). Alternatively, ROS may act by preventing the activation 
of p38 MAPK phosphatases (PPM1D, Wip1, DUSP26), implicated in inactivation of p38 by 
oxidation of the active site cysteine residue (Fig. 34) (Bulavin et al. 2002; Bulavin et al. 
2004; Yu et al. 2007). Unveiling the requirement of the above-mentioned MAPK 
phosphatases and kinases upstream of p38 in future will provide more details for the p38-
p53-p21 signaling axis activated due to Aurora B inhibition. 
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Figure 34: Regulation of p38 MAPK pathway by ROS. 
ROS affects the p38 MAPK cascade by regulating its upstream activators (ASK1 and MKK3/4/6) 
through regulating Trx, GSTm, PP5 and PP2C, or by having an effect on phosphatases (MKP, 
Wip1), which in turn regulate p38. Figure taken from (Kennedy et al. 2007). 
 
4.5 DNA damage pathway is not implicated in p21 induction after Aurora B 
inhibition 
Aurora B inhibition did not induce any of the well known DNA damage markers such as p-
H2A.X and phosphorylation of ATM/ATR substrates (Fig. 28A and B). Further, the finding 
that neither the ATM (KU5593) inhibitor nor the ATR inhibitor (VE821) have any effect on 
p21 induction by Aurora B inhibition, confirms that DNA damage response is dispensable 
for p21 activation (Fig. 28C and D). However it remains to be tested whether ROS 
generated due to aneuploidy is causing oxidative damage to DNA. This could be done by 
for example, measuring the 8-hydroxy-2′-deoxyguanosine (8-OHdG) levels in genomic 
DNA. DNA damage is a well-known contributor towards activation of p53 through 
activation of ATM pathway (Shiloh and Ziv 2013) and opposing forces at a merotelicaly 
attached centromere from the spindle poles or randomly segregating chromosomes stuck 
at the cleavage furrow might cause DNA damage (Janssen et al. 2011). However similar 
to findings in this study, Thompson and Compton (2010) also did not observe generation 
of p-H2A.X foci after chromosome missegregations (after monastrol washout). Although Li 
et al. (2010) demonstrate that ATM is required for activation of p53 and p21 in aneuploid 
cells, they also failed to depict activation of p-Chk1/Chk2 or presence of p-H2A.X in 
aneuploid HCT116 cells and propose a noncanonical pathway for activation of ATM via 
oxidative stress. Thus interfering with Aurora B function does not activate the classical 
DNA damage response (which activates ATM/ATR kinases resulting in generation of p-
H2A.X foci). 
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4.6 Cell cycle arrest due to Aurora B inhibition depends on p21 and E2F 
target genes 
One aim of this study was to investigate the requirement of CDK inhibitor p21 and genes 
regulated by E2F/pRb pathway in mediating cell cycle arrest after Aurora B inhibition. 
Absence of p21 (in case of HCT116 p21 null cells) or inhibition of the retinoblastoma 
protein (pRb) by SV40-Large T antigen increases the percentage of polyploid cells upon 
Aurora B inhibition (Fig. 15A and D), due to failure of cells to undergo cell cycle arrest.  
This finding demonstrates that p21 and pRb proteins are required for mediating cell cycle 
arrest after Aurora B inhibition. Aurora B inhibition by ZM447439 de-phosphorylates the 
pRb protein (Fig. 15B, lane 2). Since Aurora B is known to phosphorylate pRb at serine 
780 (Nair et al. 2009), the cell cycle arrest after Aurora B inhibition could be due to its 
direct effect on pRb. Alternatively, it might be an indirect effect by p21, which is induced 
due to Aurora B inhibition and blocks the cyclin/CDK complexes, required to keep pRb in 
hyper-phosphorylated (p-pRb) form, resulting in formation of the hypo-phosphorylated 
form of Rb (pRb), which causes a decrease in E2F gene transcription leading to cell cycle 
arrest. The finding that inhibition of p21 induction by SB202190 co-treatment restores the 
hyper-phosphorylated form of pRb (Fig. 15B, lane 4) supports the second hypothesis. 
Hence, pRb protein is not required for p21 induction (conclusion from Fig. 12), but it is 
required for cells to undergo arrest after Aurora B inhibition. This finding supports the use 
of Aurora B inhibitors for pRb null/non-functional tumors, as in such cases the tumors will 
continue dividing because of their inability to mount cell cycle arrest and finally die by 
apoptosis, although this has to be demonstrated in suitable experimental systems. 
 
4.7 Drugs to which aneuploid cells are sensitive synergize with Aurora B 
inhibitors, to inhibit cell proliferation via a cooperative effect on 
induction of cell cycle inhibitor proteins 
Long-term treatment of U2OS and HCT116 cells (seeded at very low density) with low 
doses of ZM447439 does not affect (or slightly reduces in case of U2OS cells) their ability 
to proliferate and form colonies (Fig. 31A and B). However combining low doses of 
ZM447439 with AICAR (a chemical compound that activates AMPK and induces energy 
stress) (Corton et al. 1995) or with 17AAG (a chemical compound that inhibits proper 
protein folding by inhibiting the chaperone Hsp90) (Young et al. 2001) significantly 
prohibits the ability of these cancer cells to grow and form colonies (Fig. 31A and B). On 
the other hand treatment with 17AAG alone has no impact and AICAR alone slightly 
restrains the colony formation ability of both the cell lines. HCT116 cells have the ability to 
grow independent of anchorage when seeded in media with soft agar, which is drastically 
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reduced in the combined presence of AICAR and low doses of ZM447439 (Fig. 31C). 
AICAR and 17AAG selectively kill aneuploid cells without having any impact on euploid 
cells due the disturbed energy balance and proteotoxic stress in aneuploid cells (Tang et 
al. 2011). Requirement of extra energy for transcription, translation and degradation of 
proteins produced from the extra copies of genome imposes energy stress, metabolic 
stress and proteotoxic stress on aneuploid cells (Stingele et al. 2012; Oromendia and 
Amon 2014). One possible molecular explanation for this co-operative ability of Aurora B 
inhibitor ZM447439 and AICAR/17AAG in impeding cell-growth is augmentation of 
induction of cell cycle inhibitors p21, p53 and p27 (Fig. 32A, B and C). The combined 
treatment induces more p21, p53 and p27 at very early time points as compared to 
treatment with AICAR, 17AAG or ZM447439 alone. Co-treatment of ZM447439 with 
AICAR was more effective in colorectal carcinoma cell line (HCT116) and with 17AAG 
was more effective in osteosarcoma cell line (U2OS). These different sensitivities might 
be due to different set of mutations in these two types of cancers and detailed 
understanding of genetic background of these cell lines will provide information about the 
mechanism of action of these drugs as well as help develop targeted therapies for 
subgroups of tumors with common markers/mutations. AICAR and 17AAG had no 
cooperative affect on phosphorylation of p38 MAPK caused by ZM447439 alone (data not 
shown), indicating that they induce p21 and p53 through an independent pathway that 
does not requires p38. Also the combination of ZM447439 and AICAR/17AAG did not 
alter the apoptotic pathway (as determined with apoptotic markers such as cleaved-PARP 
and cleaved-caspase) and the activation of autophagy markers (LC3, p62 and Hsp70) 
(data not shown).  
In support of these findings are data from yeast, where presence of one extra 
chromosome sensitizes them towards proteasome inhibitors, due increased burden on 
proteasome system to clear poly-ubiquitinated proteins for degradation (Torres et al. 
2007). Primary MEFs which become spontaneously aneuploid due to a compromised 
spindle assembly checkpoint (SAC) (as a result of impaired BubR1 allele or by checkpoint 
resistant Cdc20 allele) are also sensitive to AICAR and 17AAG (Tang et al. 2011). In the 
future it will be important to validate the effects of combined Aurora B inhibitor and 
AICAR/17AAG in in-vivo xenograft mouse models. These results suggest that 
combinations of low doses of Aurora B inhibitor with certain drugs to which aneuploid cell 
are sensitive might be effective for cancer therapy. This will not only increase the efficacy 
of Aurora B inhibitors, but also lead to fewer side effects due to usage of low doses of 
Aurora B inhibitors. Currently both AICAR and 17AAG are in clinical trials (Gordon et al. 
2012). The combination of Aurora B inhibitors with the classes of drugs that interfere with 
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the metabolic balance and proteostasis of cells certainly needs to be tested in trials going 
on clinic.  
 
4.8 Hypothesis and working model 
Taken together, the findings of this study provide evidence for a yet unknown role of the 
p38 MAPK in transcriptional elongation of the p21 gene and present sufficient details of 
the signaling pathways downstream of Aurora B which support the use of combination 
Aurora B inhibitors with drugs to which aneuploid cells are sensitive, for treatment of 
cancer. We propose the following working model (Fig. 35): Impairment of Aurora B kinase 
function by chemical inhibitors (ZM447439/AZD1152-HQPA) or by siRNA mediated 
knockdown results in stabilization of p53 as proposed by (Gully et al. 2012) and induces 
its binding to the p53 binding site (p53BS1) in the p21 gene promoter. However this 
binding is not sufficient for p21 activation because p38 MAPK, which is also activated by 
Aurora B inhibition is required for mediating the transcriptional elongation of p21 gene by 
inducing the recruitment of the elongating form of RNA Polymerase II (P-Ser2-RNA 
Polymerase II) to the p21 coding region, resulting in transcriptional induction of p21 gene. 
Activation of p38 MAPK in turn correlates with generation of aneuploidy and depends on 
generation of reactive oxygen species (ROS). Further, the induced p21 leads to 
dephosphorylation of retinoblastoma protein (pRb) owing to the ability of p21 to inhibit 
cyclin-CDK complexes, which are required to maintain pRb in phosphorylated state 
(inactive state). The resulting inactive pRb-E2F complexes prevent expression of E2F 
target genes and hence block G1-to-S transition causing G1 arrest. 
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Figure 35: Model for p21 induction and cell cycle arrest due to Aurora B inhibition. 
See text for details. 
Parts of this figure were published in similar form in Kumari et al. 2013 and Kumari et al. 2014. 
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5 Summary !
Aurora B is a mitotic kinase that is essential for cell division. Because it is mutated or 
overexpressed in a range of cancer types, it has been suggested as a novel therapeutic 
target. Currently chemical inhibitors against Aurora B are in various phases of clinical 
trials for treatment of solid tumors and leukemia. Information regarding the molecular 
requirements for the reported phenotypes of Aurora B inhibition such as cell cycle arrest, 
activation of the tumor suppressor p53 and its target p21 are not well understood.  
In this study, I investigated the requirements for p21 induction after Aurora B inhibition. I 
found that p38 is phosphorylated and activated when Aurora B is inhibited. Experiments 
with chemical inhibitors against p38 indicate that p38 is required for p21 induction and cell 
cycle arrest in response to Aurora B inhibition. p53 induction after impairment of Aurora B 
function and the recruitment of p53 to its binding site in the p21 gene promoter occur 
independently of p38 signaling. Instead, I found that p38 is required for the enrichment of 
the elongating RNA Polymerase II in the coding region of the p21 gene. Furthermore, p38 
is required for formation of the full-length p21 mRNA transcript. These data indicate that 
p38 promotes the transcriptional elongation of p21 gene in response to Aurora B 
inhibition. In further experiments I could show that the p21 causes cell cycle arrest due to 
a decrease in E2F-dependent transcription by promoting the dephosphorylation of the 
retinoblastoma protein. 
Using synchronized cells I could show that the induction of p21 in response to Aurora B 
inhibition requires transition through an aberrant mitosis and does not occur in cells that 
are arrested in interphase. Interestingly, p38, p53 and p21 are already induced by partial 
inhibition of Aurora B, which results in aneuploidy but not in cytokinesis failure and in 
tetraploidy. This supports the notion that activation of p38-p53-p21 signaling correlates 
with aneuploidy but not with tetraploidy or binucleation. Partial inhibition of Aurora B also 
leads to increased generation of reactive oxygen species (ROS), which are required for 
the activation of p38, p21 and cell cycle arrest. Based on these observations I propose the 
following model: Inhibition of Aurora B leads to chromosome missegregation resulting in 
aneuploidy.  This results in increased generation of ROS (reactive oxygen species) 
possibly through proteotoxic stress caused by an imbalance of protein synthesis in 
aneuploid cells. ROS triggers the activation of p38, which then stimulates the 
transcriptional elongation of p21 resulting in cell cycle arrest. 
Aneuploidy, proteotoxic stress and oxidative stress are hallmarks of cancer cells. Based 
on my results reported in this study, I suggest that the combination of Aurora B inhibitors 
with drugs that specifically target aneuploid cells might be a novel strategy for cancer 
therapy, as this is a lethal combination for proliferation of cancer cells. 
!!
!
Zusammenfassung 
!
! !
94!
6 Zusammenfassung 
 
Aurora B ist eine mitotische Kinase, die entscheidende Funktionen in der Zellteilung 
ausübt. Aurora B ist außerdem in einer Vielzahl von Krebsarten mutiert oder 
überexprimiert. Daher ist die Aurora B Kinase ein attraktives Ziel für die Tumortherapie. 
Gegenwärtig werden Aurora B-Inhibitoren zur Behandlung von soliden Tumoren und 
Leukämien in verschiedenen klinischen Studien getestet. Es fehlen jedoch Informationen, 
welche molekularen Mechanismen den beschriebenen Phänotypen wie Zellzyklusarrest, 
Aktivierung des Tumorsuppressors p53 und seines Zielgens p21 nach  Aurora B-
Hemmung zugrunde liegen. 
Hauptziel dieser Arbeit war es die Mechanismen der p21-Induktion nach Hemmung von 
Aurora B zu untersuchen. Es konnte gezeigt werden, dass nach Hemmung von  Aurora B 
die p38 MAPK phosphoryliert und somit aktiviert wird. Experimente mit p38-Inhbitoren 
belegen, dass p38 für die Induktion von p21 und den Zellzyklusarrest benötigt wird. Die 
Stabilisierung von p53 nach Aurora B-Inhibition und die Rekrutierung von p53 an den p21-
Genpromotor erfolgen jedoch unabhängig vom p38-Signalweg. Stattdessen ist p38 für die 
Anreicherung der elongierenden RNA-Polymerase II in der kodierenden Region des p21-
Gens und für die Bildung des p21 mRNA Transkripts notwendig. Diese Daten zeigen, 
dass p38 transkriptionelle Elongation des p21-Gens nach Aurora B Hemmung fördert. In 
weiteren Untersuchungen konnte ich zeigen, dass die Aurora B-Hemmung zu einer 
Dephosphorylierung des Retinoblastoma-Proteins führt und dadurch eine Abnahme der 
E2F-abhängigen Transkription bewirkt. Dies löst indirekt einen Zellzyklusarrest aus. 
Weiterhin konnte mit Hilfe von synchronisierten Zellen gezeigt werden, dass p21 nach 
Durchlaufen einer abnormalen Mitose induziert wird, jedoch nicht nach Aurora B-
Hemmung in der Interphase. Interessanterweise werden p38, p53 und p21 schon bei 
partieller Inhibition von Aurora B aktiviert. Die partielle Inhibition von Aurora B führt zu 
chromosomaler Instabilität aber nicht zum Versagen der Zytokinese und zur Bildung 
polyploider Zellen. Damit korreliert die Aktivierung des p38-p53-p21-Signalweges nicht mit 
Tetraploidie sondern mit vermehrter Aneuploidie. Die partielle Hemmung von Aurora B 
führt außerdem zur vermehrten Entstehung von reaktive Sauerstoffspezies (ROS), welche 
für die Aktivierung von p38, p21 und für den Zellzyklusarrest benötigt werden. Basierend 
auf diesen Beobachtungen kann folgendes Modell postuliert werden: Die Hemmung von 
Aurora B führt zu Fehlern in der Chromosomenverteilung in der Mitose und damit zu 
Aneuploidie. Dies führt zu vermehrter Produktion von ROS, möglicherweise durch 
proteotoxischer Stress, hervorgerufen durch die Imbalanz der Proteinbiosynthese in 
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aneuploiden Zellen. ROS bewirkt eine Aktivierung der p38 MAPK und trägt damit zur 
Induktion von p21 und dem resultierenden Zellzyklusarrest bei.  
Aneuploidie, proteotoxischer und oxidativer Stress stellen Schlüsselmerkmale von 
Tumorkrankungen dar. Anhand der Ergebnisse dieser Arbeit könnte die Kombination von 
Aurora B-Hemmstoffen mit Medikamenten, die gezielt aneuploide Zellen angreifen, in 
Tumorerkrankungen therapeutisch wirksam sein. 
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ATM Ataxia telangiectasia mutated 
ATR Ataxia telangiectasia and Rad3-related protein 
BrdU Bromodeoxyuridine 
BSA Bovine serum albumin 
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CDK Cyclin-dependent kinase 
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Ctrl. Control 
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dNTP Deoxyribonucleotide triphosphate 
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e.g. Example 
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Fig. Figure 
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h Hours 
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Hsp90 Heat shock protein 90 
HU Hydroxyurea 
IF Immunofluorescence 
IP Immunoprecipitation 
kDa kilodalton 
LB Luria broth 
LiCl Lithium chloride 
MAPK Mitogen-activated protein kinase 
MgSO4 Magnesium sulphate 
M phase Mitosis and cytokinesis 
NP-40 Nonylphenoxylpolyethoxyl-ethanol 
O/N Over night 
PBS Phosphate buffer saline 
PCR Ploymerase chain reaction 
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pH3 phospho histone H3 (Ser10) 
PI Propidium iodode 
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qPCR Quantitative real time PCR 
RNA Ribonucleic acid 
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rpm Revolutions per minute 
SDS Sodium dodecyl sulfate 
shRNA short hairpin RNA 
siRNA small interfering RNA 
S-phase Synthesis phase 
TAE Tris-acetate-EDTA 
TBS Tris-buffered saline 
TBST Tris buffered saline-Tween 
TEMED N’N’N’N’-tetramethylenediamine 
Tris Tris(hydroxymethyl)aminomethane 
UV Ultra violet light 
WT Wild type 
17AAG 17-N-allylamino-17-demethoxygeldanamycin 
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